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Summary
Nanoscale visualisation of live cells and cellular components under physiological conditions
has long been a goal in microscopy. The objective of this study was to validate the use of
Atomic Force Microscopy (AFM) as a new tool in unravelling the mysteries of antimicrobial
peptide mechanism of action. Using the simplest AFM imaging technique, we were able to
analyse the influence of haemolytic melittin and anti-bacterial magainin 2 on different target
membranes at nanometer resolution, without using fixing agents.
First, magainin 2 was synthesised and purified by gel permeation chromatography and high
performance liquid chromatography (HPLC). The purity of magainin 2 and melittin, isolated
from bee venom (Sigma-Aldrich), was verified with electro spray ionisation mass spectrometry
(ESI-MS). Second, dose-response experiments were used to determine the optimum
peptide/target cell ratio that would allow interaction with the membrane without causing lysis.
Third, peptide/target-cell samples were placed on silica plates and visualised using contact
mode AFM. Images obtained of the cells before and after peptide treatment, showed distinct
changes in cell membrane surface topology. We observed grooves, lesions, membrane
collapse and vesiculation depending on the concentration, type of peptide and target-cell
used, allowing us to make conclusions regarding the mechanism of action of melittin and
magainin 2.
In comparison with model membrane studies, our AFM results show that a peptide can
function by more than one mechanism of action depending on the structural composition of
the membrane, which appears to have specific segregated lateral organisation. Magainin 2
(non-toxic) selectively targets cell membranes using different mechanisms of action. In this
way it can lyse bacterial membranes (anti-bacterial agent) using one mechanism, while using
another mechanism to interact with mammalian cells at physiological concentrations, without
destroying them. In contrast, melittin (toxic) is non-selective, and uses the same mechanism of
interaction with bacterial and mammalian cells.
In conclusion, we propose a new holistic model for the mechanism of action of antimicrobial
peptides.
Stellenbosch University http://scholar.sun.ac.za
iv
Opsomming
Nanoskaal visualiseering van lewende selle en sellulêre komponente onder fisiologiese
toestande is al 'n geruime tyd 'n mikpunt in mikroskopie. Die doel van hierdie studie was om
antimikrobiese peptiede se meganisme van werking op teikenselle op nanoskaalvlak met AFM
te visualiseer. Sonder om fikseermiddels by te voeg, het ons die eenvoudigste AFM tegniek
gebruik om die effek van hemolitiese melittien en anti-bakteriële magainin 2 op verskillende
teikenselle, in nanometer resolusie, waar te neem.
Eerstens is Magainin 2 gesintesiseer en gesuiwer met behulp van gelpermeasie chromatografie
en hoë doeltreffenheid vloeistof chromatografie (HPLC). Die suiwerheid van magainin 2 en
kommersiële bye gif melittien, is bevestig met behulp van elektrosproei-ionisasie
massaspektrometrie (ESI-MS). Tweedens, is dosis-respons eksperimente gebruik om die
optimale peptied/teikensel verhouding te bepaal voordat membraanliese plaasvind. Derdens, is
peptied/teikensel monsters op silika plate gevisualiseer met gebruik van kontak AFM. Die
beelde van die selle, voor en na peptied behandeling, het duidelike veranderinge in
seltopologie getoon. Ons het groewe, letsels, membraaninstorting en vesikulasie, afhangende
van die konsentrasie peptied en teikensel gebruik, waargeneem. Dit het ons toegelaat om tot
gevolgtrekkings te kom aangaande die meganisme van werking van melittien en magainin 2.
In ooreenstemming met model membraan studies, het ons AFM resultate gewys dat 'n peptied
veelvoudige meganismes van werking kan hê, afhangend van die strukturele samestelling van
die membraan, wat klaarblyklik laterale segregasie toon. Magainin 2 (nie-giftig) is selektief
ten opsigte van teikenselle omdat dit gebruik maak van verskillende meganismes van werking
op bakteriële en soogdier selle. In teenstelling is melittien (giftig) nie-selektief, en gebruik
dieselfde meganisme van werking op bakteriële en soogdierselle.
Tenslotte, stelons 'n nuwe model vir die meganisme van werking voor.
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Preface
Model membrane studies have provided brilliant groundwork towards a better understanding
of antimicrobial peptides and their mechanism of action. However, they fail to capture many
biological features found in natural membranes, which in turn, influence the interaction with
antimicrobial peptides. In order to take our understanding to the next level, alternative
techniques are required for studying biological membranes. This thesis describes atomic force
microscopy (AFM) as alternative technique for the analysis of the mechanism of action of
antimicrobial peptides.
Chapter 1 provides a general overview of the influence that both antimicrobial peptides and
lipid composition have on the mechanism of action. It also details the shortcomings of model
membrane studies and the alternatives found in techniques such as AFM. Chapter 2 details the
synthesis and purification of magainin 2. In Chapter 3 I discuss the optimisation of the AFM
technique and the results achieved for melittin and magainin 2 on erythrocytes and E.coli. A
revised version of this chapter is in preparation for publication. In Chapter 4 an integrated
overview of the work is given together with a new holistic model leading into the future
prospects of this study.
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Chapter 1
Visualising the influence of antimicrobial peptides on target
cell membranes
1.1 Introduction
During the course of evolution, organisms have increased their ability to defend themselves
against pathogens by producing specialised substances that protect them against microbial
invasion. Consequently, bacterial resistance to conventional antibiotics has become a major
problem worldwide, with certain strains of bacteria already resistant to all available drugs [1-
2]. Clearly, the development of a new family of antibiotics is a pressing issue. Antimicrobial
peptides are considered strong candidates, because their proposed mode of action is different
from conventional antibiotics. The major problem facing scientists is that most antimicrobial
peptides are not only toxic to microorganisms, but also to mammalian cells. Therefore,
research is currently focused on improving the potency and specificity of these peptides so
that they only target microbes. In order to achieve this goal, it is important to understand the
mechanism of action of these agents and the reasons for their selectivity against microbes.
1.1.1 Types of antimicrobial peptides
There is no doubt that the overwhelming structural diversity of antimicrobial peptides has
obscured a clear understanding of their mechanism of action. Although this complicates the
design of improved synthetic agents, it does shed a positive light on the broad range of
opportunities available for future development.
We can categorise antimicrobial peptides (Table 1.1), some of which fall into more than one
category, according to the following structural properties: (i) linear peptides (most of which
have a-helix secondary structures); (ii) linear repeat-motif peptides (with a high frequency of
one or more amino acids); (iii) peptides with a single loop structural motif which could be N
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Table 1.1 Antimicrobialpeptide categories
PEPTIDE SEQUENCE
Linear
Magainin 2 (amphibian) GIGKFLHSAKKFGKAFVGEIMNS
Melittin (bee venom)
Alamethicin (fungus)
Linear repeat-motif
Bactenecin
(bovine neutrophils)
Indolicin
(bovine neutrophils)
Single-loop
GIGAVLKVLTTGLPALISWIKRKRQQ-Am
Ac-UPUAUAQUVUGLUPVUUEQF
RL C RIVVIRV C R·
I I
ILPWKWPWWPWRR-Am
Brevinin IE (amphibian) FLPL LAGL AANF LPKIF CKIT R KC
I I
Multiple-loop
a-defensin HNP-l
(human)
{J-defensin BNBD-12
(bovine)
Tachyplesin 1 (crab)
Protegrin 1
(porcine leukocytes)
Nisin
(gram-positive bacteria)
A Y f RIPA F IAGERRYGTf IYQGRLWAFI C
GLPS CGRNGGV ICIPIR ICPVPMRQIGTF FGRPVKf=I I! I J
KW C FRV C YRGI C YRR CR-Am
I I I I
CRSW
I
RGGRL C Y C RRRFC VC VGR
I I I I
IbAlaLA a PGA KaGALMGANM KaAa A HASIHVaK
Ls_j Ls_j Ls_j Ls~ I
-5-
Am = Amide; • = also falls in single loop category;
solid line = disulphide bonds; S= thio-ether bonds; a= 2,3-didehydroalanine;
b= 2,3-didehydrobutyrine; a= a-aminobutyrate
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to C, disulphide or thio-ether bonded; (iv) peptides with multiple loops due to disulphide or
thio-ether bonds (most of which have predominately ~-sheet secondary structures).
1.1.1.1 Linear peptides
Most linear antimicrobial peptides have a-helical structures, are cationic, and show an
amphipathic character. Some well known examples include PGS and the 23-residue non-
haemolytic magainins, both found on amphibian skin [3]. Magainin and several analogues
have shown a wide range of activity against gram-positive and gram-negative bacteria [4,5],
and fungi [5]. They also show activity against malarial parasites [6], protozoa [5], and a
variety of human and murine tumor cells [7-9]. Magainin has been shown to form toroidal
anion selective pores in membranes [10,11]. Two other well-known examples include
haemolytic 26-residue bee-venom melittin [12], and non-toxic 37-residue giant silk moth
cecropin A [13]. These two peptides are structurally similar and are active against gram-
positive and gram-negative bacteria, and show lytic activity against target cells. It has also
recently been shown that they inhibit HIV transcription [14]. Melittin has also been shown to
have antiviral activity by direct lysis and inhibition of replication. [15,16].
There are also a-helical peptides that are hydrophobic or sometimes even slightly anionic.
Alamethicin, produced by the fungus Trichoderma viride is a well-studied example and forms
part of a group known as the peptaibols, which are characterized by having a high proportion
of a-amino-isobutyric acid (Aib) residues [17]. In addition, these peptides are lipopeptides,
which are acylated at the N-terminal. The name of this group is derived from the fact that they
have an 1,2-amino alcohol at the C-terminal [17]. Alamethicin has been shown to form a-
helical clusters that traverse the bilayer and surround an aqueous pore that can transport ions
[18]. Another peptide that is hydrophobic and forms a helical transmembrane structure is
gramicidin A [19]. In membranes it forms a cation-selective right-handed ~-helix that
traverses the membrane as a single-stranded head-to-head dimer [20]. Both alamethicin and
gramicidin A show minimal selectivity between microbes and mammalian cells, limiting their
pharmacological applications.
Stellenbosch University http://scholar.sun.ac.za
1.4
1.1.1.2 Linear repeat-motif peptides
Certain peptides have an amino acid composition that is rich in one or more specific amino
acids. For example, histatins are produced in human saliva and form part of a histidine-rich
family active against oral cavity pathogens and the common human fungal pathogen Candida
a/bieans [21,22]. Peptides rich in arginine or proline are produced by mammal neutrophils
from cathelin-associated propeptides (cathelicidin family). Examples include bovine
bactenecin [23,24] that influences transport and energy mechanisms, and porcine prophenin
and PR-39, which have shown to inhibit DNA as well as protein synthesis [25,26]. Tritrpticin
[27] and indolicidin [28] are 13-residue peptides that also form part of the cathelicidin family
and are examples of antimicrobial peptides that are rich in tryptophan. Indolicidin appears to
permeabilise bacteria without lysing them [28] and can form conductance channels. The
formation of conductance channels suggests that indolicidin can self-associate and that the
haemolytic activity of this peptide is associated with the concentration required for its self-
association. Indolicidin is also active against human immunodeficiency virus 1 (HIV -1).
1.1.1.3 Single loop peptides
A large number of antimicrobial peptides isolated from the Rana frog species are
characterised by a large linear segment followed by a C-terminal cationic loop linked by a
disulphide bridge containing 7 amino acids. Examples include brevenins [29], gaegurins [30],
esculentin and ranalexin [31]. The C-terminal loop of brevenin IE has an amino acid
composition similar to polymyxin B and has been presumed to play an important role in its
antimicrobial activity [29]. Experiments on ranalexin analogues confirm the above
assumption [31]. Bactenecin from bovine neutrophils [23] also fall into this category together
with the class Ha or "pediocin-like" bacteriocins, which are produced by lactic acid bacteria
(LAB) [32]. The latter fall into this category because they contain two cysteines that can
possibly form a single disulphide bond. They are only active against gram-positive bacteria
with high specificity for Listeria strains [32]. Another interesting group of peptides from the
Rubiaeease plant family was recently discovered to possess antimicrobial activity and consists
of four macrocyclic end-to-end 30 amino acid residue cyclic peptides [33]. These peptides
(kalata, circulin A and B, and cyclopsychotride) also have a cysteine knot motif. The knotted
motif is the result of one disulfide bond being threaded through the other two. This structural
motif is also found in protease inhibitors and toxins and together with the cyclic backbone,
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confers high rigidity to the structure. Circulin A and B have been shown to have anti-viral
activity and may playa future role as anti-HIV drugs [34].
1.1.1.4 Multiple loop peptides
The multiple loop motif is found in the largest group of peptides and includes insect, plant and
mammalian defensins, as well as tachyplesins, protegrins, and lantibiotics.
Mammalian defensins are ~-sheet peptides with between 29 and about 40 amino acid residues
and three intramolecular cysteine-disulphide bonds [35,36]. The c- and ~-defensins differ
with respect to the placement and connectivity of their 6 cysteine residues, the structures of
their precursors and their patterns of expression [37,38]. The cc-defensins have a broad
spectrum of activity compared to the ~-defensins, which have activity limited towards gram-
negative bacteria [37,38]. Comparatively, insect defensins contain three disulphide bonds, but
there are distinct differences in sequence and secondary structure, with antimicrobial activity
limited to gram-positive bacteria [39]. Plant defensins contain three or four disulphide bonds
and their activity varies widely from being antibacterial to being highly active against plant
pathogenic fungi [40].
Other peptides include tachyplesins from the horse-shoe crab, which are all 17-residue peptide
amides consisting of two antiparallel ~-sheets separated by a ~-tum and stabilised by two
disulphide bonds. They permeabilise both bacterial and artificial lipid membranes and
translocate across lipid bilayers, which has been coupled to transient pore-formation [41].
Tachyplesin analogues are active against HIV with low cytotoxicity [42].
Protegrins are defensins that are structurally similar to tachyplesins and share their broad
spectrum of activity against bacteria, fungi, and viruses [43]. Unlike some of the larger
defensins [35], protegrins retain activity in physiological concentrations of sodium chloride.
Truncated protegrins with 12 residues manifest potent antibacterial activity, whereas the four
additional residues are required for optimal candidacidal activity [44,35].
The lantibiotics are class II bacteriocins produced by strains of Lactococcus and other gram-
positive bacteria. They are divided into two structural groups, namely group A, consisting of
linear cationic peptides with multiple loop structures (nisin, epiderma, subtilin, PEPS, and
lactocin S) and group B, consisting of small circular neutral peptides (cinnamycin, duramycin,
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and ancovenin) with mersacidin and actagardine sharing properties of both groups [32,45].
Besides lanthionine and its analogue 3-methyllanthionine, all lantibiotics contain
didehydroalanine and/or didehydrobutyrine. The most well studied lantibiotic is 34-residue
nisin, which is produced by several strains of L. lactis, and characteristic of most lantibiotics,
is very active against a wide range of gram-positive bacteria [45]. It has also been used for
over forty years as an antimicrobial agent for food preservation [46].
1.1.2 Influence of membrane structure on the mechanism of action of
antimicrobial peptides
It is generally accepted that most antimicrobial peptides, regardless of sequence, size, charge,
diastereomerism, L- or D-amino acid composition, and secondary or tertiary structure, use a
mode of action on target membranes that is not receptor-specific [47]. The strongest support
comes from studies showing that enantiomers (consisting solely of D-amino acids) of lytic
melittin, cecropin, magainin and androctonin show activity indistinguishable from their parent
molecules [48-51]. Nisin Z, however, is an exception that uses membrane anchored cell wall
precursor lipid II as a receptor [52]. Nevertheless, target-membrane selectivity of cationic
peptides has largely been attributed to prokaryote cell membranes being negatively charged,
compared with eukaryotes, which are predominantly zwitterionic. The outer surface of gram-
negative and gram-positive bacteria contains lipopolysaccharides and teichoic/lipoteichoic
acids respectively, giving both surfaces a negative charge [53]. In addition, the phospholipids
of the inner membrane of gram-negative and the single membrane of gram-positive bacteria
are also negatively charged. In contrast, the outer section of normal mammalian cells is
predominantly zwitterionic [54]. Selectivity studies on cecropins [55], magainins [56],
dermaseptins [57] and others [49,58-61] have all demonstrated a lower affinity to zwitterionic
phospholipid membranes compared to acidic phospholipid membranes. However, the
selectivity is not solely based on charge and can be influenced by the structural properties of
the specific lipid components of the target-membrane. For example, cynamycin appears to
show specificity for phosphatidylethanolamine (PE) [62] and sapecin exhibits a specific
affinity for cardiolipin (CL) [63]. Magainin has shown to permeabilise membranes composed
of phosphatidylglycerol (PG) at lower concentrations (peptide to lipid ratio (PIL) of 1:100)
than membranes composed of other negatively charged lipids such as phosphatidylserine (PS),
phosphatidic acid (PA), and cardiolipin (CL) (PIL ratios of 1:50 to 1:20) [64,65].
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These examples highlight the importance that this aspect of selectivity can have on the
mechanism of action of antimicrobial peptides when compared to the variation that occurs
among target-membranes (see Table 1.2).
Table 1.2. Phospholipid composition (Wllo)of the cytoplasmic membrane of gram-positive
and gram-negative bacteria [66,67] and human erythrocytes [68].
Species %PG %PE %CL % Other
Gram-positive bacteria:
S. aureus 57 0 43 0
Staphylococcus epidermis 90 0 9
Bacil/us megaterium 40 40 5 15
Bacil/us subtilis 29 10 47 14
Gram-negative bacteria:
Escherichia coli 6 82 12 0
Salmonella typhimurium 33 60 7 0
Pseudomonas cepacia 18 82 0 0
Human erythrocytes 0 28.4 0 70.9*
*31% phosphatidylcholine (PC), 23.5% sphingomyelin, 13% PS, 2.2%
PA and 1.2% phosphatidylinositol (PI)
A structural analysis of lipid components shows that they are predominantly arranged in a
bilayer with the polar head groups facing outwards and the non-polar acyl chain tails pointing
inward. However, alternative non-lamellar phases also exist (Fig.1.1) because the structural
properties can be either positive-curvature inducing or negative-curvature inducing [69].
Lipids with small head groups (e.g. PE and PS) promote negative curvature strain because
there is a comparatively larger cross-sectional area available for the acyl chain tails and a
smaller area is required for the head groups (Fig. 1.1). If the bilayer stress reaches a critical
point, it can result in inverted phases where the polar head groups face inwards and the non-
polar tails face outwards [69]. Alternatively, large head groups (e.g. PG and CL) promote
positive curvature strain because there is a comparatively larger cross-sectional area required
for the polar head groups and a smaller area available for the lipid acyl chain tails (Fig. 1.1). If
the bilayer stress reaches a critical point, it can result in micelles [69]. The bilayer stress of
Stellenbosch University http://scholar.sun.ac.za
Negative Curvature Strain
Stable Bilayer
Positive Curvature Strain
1.8
Inverted Phase
Strained Small Vesicle
Micelle
Figure 1.1 The figures on the left-hand side (top to bottom) represent three alternative
bilayer motifs. The lipid shapes have been exaggerated in order to emphasize the
consequences of packing into a flat structure with: a small head group (negative
curvature strain), a head group comparable to the cross-section of the acyl chains
(stable bilayer), and a large head group (positive curvature strain). The right-
hand side represents the type of curved structures that can form if the bilayer
stress reaches a critical point. The wavy lines indicate the presence of water.
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a lipid component can be stabilised or destabilised by interaction with an antimicrobial
peptide, depending on its specific structural properties. Calorimetry has been used to monitor
whether a peptide stabilises or destabilises membranes by showing an increase or decrease in
the lamellar (Lu) to inverse hexagonal (Hi i) transition temperature (TH) respectively. Wasp
venom mastoporan [70] and antimicrobial magainin [64] were shown to increase the Lu- H,
transition temperature of dipalmitoleoylphosphatidylethanolamine. In another study, melittin
was shown to stabilise PE membranes by decreasing the negative curvature stress [71-73].
Gramicidin S was shown to increase the negative curvature, destabilising PE membranes
towards the formation of non-lamellar structures [74]. Alamethicin has also recently shown to
exhibit similar destabilising ofPE membranes [75].
These examples indicate that the selectivity of antimicrobial peptides is influenced by the
specific lipid composition of the target membrane and that the extent of structural
complementarities, which occurs between peptide and lipid, can be a fundamental factor
influencing the mechanism of action used (detailed in Chapter 3).
1.1.3 Mechanism of action
1.1.3.1 Structural parameters
Several structural parameters can modulate the biological activity and mechanism of action of
linear a-helical peptides. It is, however, difficult to determine the individual importance of
each of these parameters, as they often influence each other. Nevertheless, certain trends have
emerged from studies with naturally occurring peptides and model peptides:
1.1.3.1.1 He/icily: Studies indicate that helicity is essential for activity against zwitterionic
membranes (eukaryotes), but less important for activity against negatively charged membranes
(prokaryote). Various D-amino acid substitution-studies on melittin [76], pardaxin [77] and
Lys-Leu model peptides [78] were used to disrupt helix formation. Compared to their wild-
types, the diastereomers did not bind to zwitterionic model membranes, but retained their
affinity for negatively charged membranes. This in turn correlated with a loss of haemolytic
ability, while retaining antimicrobial activity. In contrast, non-haemolytic magainin lost all of
its antimicrobial activity after helix disruption by two consecutive D-amino acid substitutions
[79], but retained its permeabilising activity on negatively charged PG membranes [80].
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1.1.3.1.2 Amphipathicity: Amphipathicity of a peptide is a measure for the spatial separation
between hydrophilic and hydrophobic side chains. It is generally determined by calculating the
hydrophobic moment, which is defined as the vector sum of the hydrophobicities of each
amino acid residue [81]. Studies using peptides consisting of repeating motifs of Lys-Leu-
Ala-Leu (KLAL-peptides) indicate that the hydrophobic moment plays a minor role in the
permeabilisation of negatively charged membranes but substantially influences their effect on
neutral membranes [82]. This parameter strongly influences hydrophobic peptide-lipid bilayer
interactions [83], and although it has been a key feature in the de novo design of simple
peptides, peptides with increased antimicrobial activity and high selectivity still remain
limited [84].
1.1.3.1.3 Hydrophobicity: A peptide's hydrophobicity reflects the intrinsic capability to move
from an aqueous phase into a hydrophobic phase. It can be expressed as the mean
hydrophobicity, defined as the average of the numeric hydrophobicity values of all residues
[85]. Natural antimicrobial peptides show a wide range of hydrophobic moments and mean
hydrophobicities. Several studies on model peptides [86-87], cathelicidin-derived peptides
[88], and analogues of brevenin IE [89] indicate that high mean hydrophobicities correlate
with high cytotoxic activity against the neutral membranes of mammalian cells. Further
studies on histatin- and magainin-derivatives [90] confirmed that haemolytic activity was
strongly correlated with mean hydrophobicity, independent of amphipathicity or net positive
charge. Other studies have addressed the relationship between hydrophobicity and
antibacterial activity, showing that no strong correlation exists [87, 91-92]. In contrast,
cecropin A-melittin studies [93] and studies using analogues of CAMELO (a IS-residue
antibacterial peptide) [94] do show a correlation between hydrophobicity and antibacterial
activity, however difficulties arise when interpreting results from different peptide studies as
they often vary in more than one parameter. KLAL-peptide analogues addressed this problem,
and the results indicated that there is a more direct relationship between hydrophobicity and
haemolytic activity than with antibacterial activity [84]. One explanation is that electrostatic
accumulation of the peptides near the negatively charged bacterial membranes reduces the
relative contribution of hydrophobicity to the overall effect [84].
1.1.3.1.4 Hydrophobic and hydrophilic angles: The angles subtended by the hydrophobic and
hydrophilic faces influence membrane binding, independent of the hydrophobicity and the
hydrophobic moment [84]. Furthermore, they also affect the induction of positive or negative
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membrane curvature strain, thereby influencing the destabilisation of lipid bilayer membranes
[84]. Brasseur et al. [95] suggested that peptides with small hydrophilic angles and high mean
hydrophobicities tend to form trans-membrane pores. A recent study [96] used model peptides
Sp100 and Sp180 with polar angles of 100° and 1800 respectively, to show that despite its
somewhat lower affinity, Sp100 exhibited higher permeabilisation activity, a greater flip-flop
rate, as well as more antimicrobial activity than Sp180 due to a higher pore formation rate.
Furthermore, the number of peptides constituting the Op100 pore was less than that of Sp 180,
and the Sp100 pores involved less lipid molecules [96]. In other studies on magainin and
KLAL peptide analogues (whereby the hydrophobicity, hydrophobic moment and the number
of charged residues were maintained constant) showed that changes in the hydrophilic angle
had little effect on the neutral lipid membranes of erythrocytes, whereas the permeabilisation
of highly charged membranes was decreased upon increase of the polar angle [84]. It should,
however, be noted that the modulating potential of the polar angle is generally connected with
the magnitude of other structural parameters.
1.1.3.1.5 Charge: Various studies using ê-hemolysin [97], magainin [98-99], and pardaxin
[100] have shown that an increase in positive charge correlates to an increase in antibacterial
activity, whereas a gradual reduction in positive charge decreases antibacterial activity [99-
100]. However, if the peptide's positive charge is increased too far, membrane activity may
decrease as strong electrostatic interactions anchor the peptide to the lipid head group
disrupting insertion into the hydrophobic core [80,101]. Furthermore, repulsion between the
positively charged side-chains (intra- or intermolecular) may obstruct the formation of pores.
Although there is no simple correlation between peptide charge and biological activity, studies
indicate that a sensitive balance between electrostatic and hydrophobic interactions determine
peptide-membrane interactions [82]. Peptide charge seems to modulate the initial membrane
interaction and selectivity, whereas biological activity appears to be driven by the hydrophobic
interaction between non-polar amino acids and the hydrophobic core of the lipid bilayer [47].
1.1.3.1.6 Oligomerisation: Pardaxin, LL-37, and peptides from the dermaseptin family are
examples of peptides that are highly positive and yet show no selectivity between bacteria and
mammalian cells [47]. A study on their mode of action revealed that peptide oligomerisation
in solution and in the membrane was an additional important parameter that controlled their
selectivity to specific targets [47]. It was revealed that those peptides which bound as
oligomers, showed no selectivity between zwitterionic and negatively charged membranes,
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whereas those peptides that were in monomer form showed selectivity for negatively charged
membranes [47]. A recent study [102] compared model peptides to their cyclic counterparts.
They found that cyclisation abolished oligomerisation of the linear peptide in solution and in
sodium dodecyl suphate (SDS), and increased selectivity between bacteria and human
erythrocytes by substantially decreasing the haemolytic activity of the cyclic peptides.
Furthermore, the linear peptide was only active toward gram-positive bacteria, whereas the
cyclic monomer peptide was active towards gram-positive and gram-negative bacteria.
Each structural parameter plays a role in the combined influence over selectivity. A summary
of all currently accepted studies can be represented by the following:
• peptides with a moderately high positive charge and a small polar angle, which exist as
monomers in solution, show high antibacterial and low haemolytic activity;
• peptides with a large hydrophobic moment, high mean hydrophobicity and a low
positive charge, which oligomerise in solution, show high antibacterial and high
haemolytic activity.
These structural trends have been incorporated into proposed models for the mechanism of
action of antimicrobial peptides. In the following section, we will highlight the most accepted
models.
1.1.3.2 "Barrel-stave" model for transmembrane channel/pore formation
The barrel-stave mechanism [103] describes the formation of transmembrane channels/pores
by bundles of amphipathic a-helices, such that their hydrophobic surfaces interact with the
lipid core of the membrane and their hydrophilic surfaces point inward, producing an aqueous
pore (Fig. 1.2). Other distinct structures such as bundles of P -sheets, or combinations of a-
helices and p-sheets are also included in this model of pore formation [47]. The structures are
orientated perpendicular to the membrane surface after insertion. The following criteria must
be fulfilled for a peptide to act via this mechanism [47]: (1) peptides bind to the membrane in
a monomeric or multimeric form, (2) monomers recognise each other in the membrane-bound
state at low surface density of bound peptide. However, if they reach the membrane as small
oligomers they do not dissociate in the membrane, (3) peptides insert in the hydrophobic core
of the membrane, (4) progressive recruitment of additional monomers or small oligomers
occurs to increase the size of the pore.
Stellenbosch University http://scholar.sun.ac.za
1.13
A crucial step in this mechanism requires peptides to recognise each other in the membrane-
bound state. Peptide-assembly can occur on the surface of the membrane [104-105], or within
the hydrophobic core [104-105], since it would be energetically unfavourable for a single
amphipathic helix to transverse the membrane as a monomer [47]. It can be assumed that
since these peptides can insert into the hydrophobic core of the membrane, their interactions
with target membranes are predominantly driven by hydrophobic forces [47]. Furthermore, if
they adopt an a-helical structure, their net charge along the peptide backbone should be close
to neutral. Peptides using this model tend to be toxic towards bacteria and erythrocytes.
Examples include pardaxin [106-107], alamethecin [108], and the helix a5 of ê-endotoxin
[109-110].
Figure 1.2. Graphical representation of the barrel-stave mechanism during multimeric
perpendicular insertion of a-helical peptides (cylinders) into the
hydrophobic core of a bilayer membrane. The orange spheres and grey rods
represent the lipid head groups and acyl side chains of a bilayer membrane
respectively.
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1.1.3.3 "Carpet" model for membrane disruption
This model was initially proposed for dermaseptin S [111] and describes a situation where
lytic peptides are in contact with the phospholipid head groups throughout the entire process
of membrane permeation. According to this model (Fig. 1.3), lytic peptides initially bind onto
the surface of the target membrane and cover it in a carpet-like manner (Fig. 1.2). Initial
interaction with the negatively charged target membrane is electrostatically driven, and
therefore most active peptides with this type of mechanism are positively charged [47]. A high
local concentration of membrane-bound peptide must be reached for membrane permeation to
occur. Higher peptide concentrations can lead to membrane disintegration. High local
concentration on the surface of the membrane depends on the type of target membrane and
can occur either after all the surface of the membrane is covered with peptide monomers, or
alternatively, after there is an association between membrane-bound peptides which form a
local carpet [47]. Contrary to the "barrel-stave" model, peptides are not inserted into the
hydrophobic core of the membrane; neither do they assemble with their hydrophilic surfaces
facing each other [47]. Furthermore, a peptide that permeates the membrane using the "carpet"
model does not require a specific length or the adoption of a secondary structure and can be
linear or cyclic upon binding to the membrane [47]. The four steps proposed to be involved in
this model are [47]: (1) preferential binding of peptide monomers to the phospholipid head
group, (2) alignment of the peptide monomers on the surface of the membrane so that their
hydrophilic surface is facing the phospholipid head groups or water molecules, (3) rotation of
the peptide monomers leading to orientation of the hydrophobic residues toward the
hydrophobic core of the membrane (4), permeating or disintegrating the membrane by
disrupting the bilayer curvature to such an extent that vesicles form. It has been proposed that
peptides using the "carpet" mechanism have a high net charge, which is spread along the
peptide chain, and they bind weakly (or not at all) to zwitterionic membranes, limiting
haemolytic activity [47]. However, highly charged peptides can lyse erythrocytes if they form
oligomers in solution. The "carpet" mechanism has been used to describe the mode of action
of natural analogues of derma sept in [112-113], cecropins [114-116], LL-37 [102], caerin 1.1
[117], trichogin GA IV [118], and diastereomers of various lytic peptides [47].
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Figure 1.3 Graphical representation of the carpet mechanism illustrating the
process of lipid perturbation due to monomeric peptide insertion in
a parallel orientation. The blue cylinders represent the monomeric
peptides. The orange spheres and grey rods represent the lipid head
groups and acyl side chains of a bilayer membrane respectively.
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1.1.3.4 "Toroidal" model
The "toroidal" (or wormhole) model [11,65] describes the formation of transient holes in the
membrane surface (Fig. 1.4). It is a variation on the lysis phase of the "carpet" model, before
the collapse of the membrane packing. These holes would enable the passage of low
molecular weight molecules prior to complete membrane lysis. The model describes changes
in peptide orientation during insertion, from horizontal to vertical, while maintaining contact
with the lipid head group. Consequently, the lipid monolayer bends inwards with the peptide,
from the top leaflet to the bottom leaflet, so that unlike the "barrel-stave" model, both the lipid
head groups and the peptides line the pore. The "toroidal" model has been proposed for the
mode of action of dermaseptin [119] magainin [11,65,120,121], protegrin [122], and recently
melittin [123].
These holes may allow the passage of peptide molecules from the outer membrane into the
inner membrane of for example, gram-negative bacteria in a process that may be referred to as
self-promoting uptake (see 1.1.3.8) [124-126].
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Figure 1.4. Graphical representation of the toroidal mechanism illustrating the intercalation
of peptides into the hydrophobic core by a parallel to perpendicular transition.
The blue cylinders represent the monomeric peptides. The orange spheres and
grey rods represent the lipid head groups and acyl side chains of a bilayer
membrane respectively.
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1.1.3.5 "Detergent-like" effects
It has been proposed that as an extension of the "carpet" model, some peptides can form
destructive peptide-lipid micelle-like structures after accumulating on the surface of
membranes in a parallel configuration [127].
Experiments were performed to test the properties of magainin 2 and the micelle-forming
detergents Triton-100 and octyl glucoside [128]. The results showed the specific activities of
magainin 2 and the detergents were similar in their ability to induce leakage of
carboxyfluorescein from PS vesicles [128]. The onset of dye leakage took place at a magainin
concentration of approximately 3 mole %. Similar results were obtained with Triton-100 and
octyl glucoside. The addition of magainin at high concentration to phospholipid bilayers
resulted in the appearance of large water-filled bilayer disruptions [11]. 31p solid state NMR
spectroscopy detected the optical clearing of dense suspensions and the formation of isotropic
phases [10]. Membrane disruptive properties have also been observed for apolipoproteins
[129], myelin basic protein [130], glucagon [131], and model peptides [132]. A recent study
on melittin [133] showed that release of markers from zwitterionic
palmitoyloleoylphosphatidylcholine vesicles was highly selective, whereas release from
negatively charged palmitoyloleoylphosphatidylglycerol vesicles was non-selective and
detergent-like.
1.1.3.6 The aggregate channel model
The aggregate channel model [134] proposes that after binding to the lipid head groups, the
peptides insert into the membrane and cluster into unstructured aggregates that span the
membrane. These aggregates are proposed to have water molecules associated with them,
creating channels for the leakage of ions and possibly larger molecules through the membrane.
This model differs from the "barrel-stave" and "carpet" models because short-lived trans-
membrane clusters of an undefined nature are formed, which allow the peptides to cross the
membrane without causing significant membrane depolarisation. Once inside, the peptides
find intracellular targets to exert their killing activities [134].
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1.1.3.7 Intracellular targets of antimicrobial peptides
A number of studies indicate that the biological activity of certain antimicrobial peptides is
due to interference with intracellular targets or processes. The glycine-rich attacins block the
transcription of the amp gene in Escherichia coli [135], whereas magainins and cecropins
induce selective transcription of E. coli stress-related genes micF and osmY at sublethal
concentrations [136]. Bac 5 and Bac 7 inhibit protein and RNA synthesis of E. coli and
Klebsiella pneumoniae by inhibition of respiration, in addition to their potential to disturb the
membranes of these bacteria [88]. Buforin II [137] and PR-39 [138,26] also bind to the cell
membranes of E.coli without causing permeabilisation and subsequently destroys the bacteria
by stopping both DNA and protein synthesis. Histatin 5 and histatin 3 can pass the
cytoplasmic membrane of Candida albicans [139-141], and histatin 5 targets the
mitiochondria [140].
1.1.3.8 Self-promoting uptake pathway of gram-negative bacteria
In gram-positive bacteria, cytoplasmic membranes are surrounded by several layers of
peptidoglycan containing lipoteichnoic acid (LTA), whereas the cytoplasmic membrane of
Gram-negative bacteria are surrounded by outer lipid membranes containing cell-surface
lipopolysaccharides (LPS). It has been suggested that LPS plays a role in the transport of
peptides through this outer membrane [142]. In the proposed self-promoting uptake pathway,
cationic peptides bind to LPS, competitively replacing Ca2+ and Mg2+, essential for cell
surface stability, from their divalent binding sites. This is thought to cause openings in the
LPS surface through which small molecules and peptides can pass [142]. This pathway
putatively explains the synergy found between several antimicrobial peptides and classic
antibiotics acting against gram-negative bacteria [142-144]. However, synergistic effects
between peptides and antibiotics have also been found for gram-positive bacteria [145] and C.
albicans [146].
1.1.3.9 Antiviral Activity
Several antimicrobial peptides also display antiviral activity in vitro. Defensins neutralise
herpes simplex virus (HSV), vesicular stomatitis virus, and influenza virus [146].
Tachyplesins [147], polyphemusins [147], melittin [14], cecropin [14], and indolicin [148]
displayanti-HIV activity. The generally accepted mechanism of antiviral action is analogous
to the pore-forming models suggested for antibacterial activity, whereby interaction of the
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peptides with the virus envelope leads to permeation and lysis of the virus particle. However,
other mechanisms have been proposed for peptide T22 that inactivates HIV -1 in vitro by
binding to the gp120 protein of the virus and the CD4 receptor ofT-helper cells. This binding
of T22 may block virus-cell fusion in the early stage of the infection [147]. Melittin and
cecropins inhibit the replication of HIV -1 by suppression of the expression of the long
terminal repeat gene [14].
Each structural parameter plays a role in the combined influence over the mechanism of action
of a specific peptide, with the "barrel-stave" model and the "carpet" model representing the
opposing poles of all currently accepted models. Many studies are still required before our
understanding of the mechanism of action of antimicrobial peptides reaches the level of
widespread therapeutic development. The main limiting factor is that the techniques being
used are most effective in model membrane systems and therefore alternative methods for the
study of natural membrane targets should be explored.
1.2 Visualisation of antimicrobial activity
The availability of analytical and preparative techniques has allowed the application of many
biophysical methods for determining the orientation, conformation, and interaction of peptides
with lipid membranes, in an attempt to unravel the mechanism of action [10]. These include
X-ray crystallography [121,149], nuclear magnetic resonance (NMR) in solution [150] and in
the presence of lipid bilayers [150], as well as Fourier transform infrared (FTIR) [151],
Raman- [10], fluorescence- [10,151] and circular dichroism (CD) spectroscopy [10,152]. The
main reason for the difficulties in establishing a direct correlation between the lipid interaction
and the conformation and orientation of peptides is the lack of experimental model systems
that mimic the complexity of natural cell membranes. Model systems fail to capture biological
features such as lipid heterogeneity, the presence of membrane proteins and relevant features
in the periplasm adjacent to the membrane (proteins, negatively charged membrane-derived
oligo saccharides, osmolarity, and pH), as well as membrane potential and the pH gradients
across the cytoplasmic membrane, etc. Furthermore, methanol, ethanol, acetonitrile,
1,1,1,3,3,3-hexafluoroisopropanol, SDS, and trifluoroethanol (TFE) are the most frequently
used membrane-mimetic organic co-solvents to determine the induced conformations relevant
to antimicrobial activity [153-154]. However, the induced conformations do not necessarily
reflect the peptide conformation upon interacting with lipid surfaces. For example, pardaxin
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was shown to adopt a helical or ~-sheet conformation depending on whether lipid vesicles or
different concentrations of TFE or SDS were used in the experiments [100,155]. The
secondary structure of magainin differed between TFE-water mixtures and lipid environments
[156,157]. Another example is the significantly different conformations reported for melittin
in the presence of detergent micelles and TFE [158].
Even though the structure of many peptides are well established by means of the above-
mentioned techniques, the orientation and structure of these peptides in membranes remains
controversial (Table 1.3), and conclusions regarding the mechanism of action vary, depending
on the experimental methodology. An alternative could lie in combining the structural
information obtained from these indirect techniques with the latest advances in microscopy to
validate antimicrobial peptide mechanism of action. After all, seeing is believing.
Model Membrane Peptide:Lipid Ratio Orientation of bulk Reference
of melittin molecules
DPhPC 1:30 Parallel (23°C) 123
DMPC 1:100 Perpendicular (35°C) 123; 151
DMPC 1:100 Parallel (15°C) 151
DLPC 1:30 Perpendicular _(23°C)_ 123
DOPC 1:100 Parallel (23°C) 189
POPC 1:15 68% perpendicular 123
(23°C)
POPc 1:40 85% parallel (23°C) 123
POPc 1:50 Perpendicular (45°C) 133
Table 1.3 Variations in the orientation of melittin because of changes in lipid composition
and peptide concentration.
Abbreviations: 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC), 1,2-
dimyristoyl-sn-glycero- 3-phosphocholine (DMPC), 1,2-dilaueroyl-sn-glycero- 3-
phosphocholine (DLPC), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC).
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1.2.1 Microscopy
To visualise the effects of antimicrobial peptides on target membranes resolution in the
nanometer range is required. Many techniques are available with resolution that ranges from
micrometers in the case of light microscopy, through to the sub-nanometer range for electron
microscopy. Electron microscopes are now available that give point-to-point resolutions of
less than 0.2 nanometers [159], but the sample needs to be treated or fixed. In the case of cell
membranes, it would result in conformational changes of the peptide and membrane surfaces.
This limits the applications and conclusions concerning the mechanism of action of
antimicrobial peptides. Various other microscopy techniques are available (polarizing,
reflecting, phase-contrast, fluorescence and acoustic microscopy to name a few), but sample
treatment is always required to obtain resolution in the nanometer range [160]. However, the
last decade has seen rapid development in the field of scanning probe microscopy [161].
Scanning probe microscopes can create three-dimensional (3D) images down to the atomic
scale. They function in air, liquid as well as in vacuum, and use a technique for which
biological specimens need no staining or fixing [162]. In addition, they can map electronic,
mechanical, and optical properties, furthermore, they can even manipulate a surface to the
level of moving atoms one by one. The entire scanning microscopy family is based on the
invention of scanning tunnelling microscopy (STM) by Binnig et al. [163] in 1982. All these
techniques are based on a deceivingly simple principle whereby a sharp probe interacts with a
specimen by raster scanning its surface, providing three-dimensional information in the form
of a computer generated image.
Many different physical principles have been used for imaging. These include photo
tunnelling with a fibre-optic tip (scanning near-field optical microscopy) [164-165] magnetic
interaction with a magnetised probe (scanning magnetic microscopy) [166-167], surface
repulsive forces (atomic force microscopy, AFM) [168-169], and ion conduction with a glass
pipette [170]. The resolution of these different techniques varies from micrometers into the
sub-nanometer range and depends critically on the geometry of the tip and the nature of the
interaction. AFM [168] and STM [163] are arguably the most versatile and widely applied in
the various fields of research.
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Historically, there is normally a long delay for any new imaging method to make headway in
biological research. A well-known example is electron microscopy [171]. Even after the first
images of biological samples were published, the general perception amongst biologists was
not very positive [160]. The reason is that most biological structures were thought of as very
delicate and could easily be damaged, raising the question whether the information gathered
was entirely relevant to in vivo biological structures. It took many years of persistent effort in
the development of specimen preparatory techniques and in cross-corroboration with other
methods that finally established electron microscopy as a credible method in biology [171-
173]. Nowadays, electron microscopy is an essential part of structural research in cell biology
and is becoming increasingly important in obtaining structural information, even at atomic
resolution. This slow evolution was in sharp contrast with the case of STM and AFM in
biology. It took only a few years after the invention of STM before the first images of a
biological sample (DNA) were published, claiming the resolution of the double helix pitch or
even of the individual bases [174-175]. These images stirred a burst of enthusiasm among
researchers from a broad-spectrum of backgrounds [176]. However, because STM requires
that a current be passed through the sample, artefacts due to substrate deformation and the
inability to understand the contrast formation in these non-conductive structures, generated
serious doubts about the validity of the STM images [177]. Admittedly, many of these earlier
images were poorly reproducible and the experiments were not conducted with rigorous
control [176]. Since AFM does not require that a current be passed through the sample, it
became the favoured choice for biological imaging. However, reproducibility due to sample
deformation was still a problem but the mechanism of image formation was simpler. These
earlier difficulties created a rather negative perception about STM and AFM in general, and
the future of these novel technologies in biology was seriously questioned [176-177].
The real breakthrough came with improved preparative methodologies. In 1992, Bustamante
et al. [178] published the first credible DNA images in air, with a resolution favourably
comparable with that of conventional electron microscopy [179]. Within a few months,
several other reports of DNA were also published with similar or different preparatory
methods at a similar resolution [180], strongly supporting the validity and reproducibility of
AFM. From these results, it became clear that AFM was not responsible for the difficulties,
but rather the methods of sample preparation, which lead to a rapid development of different
techniques, that continues today [181].
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At this stage, the emphasis of scanning probe microscopy (SPM) has almost entirely shifted to
AFM, with many interesting images being published and resolution improving into the
nanometer domain [181]. This rapid development is mainly because structural information
about macromolecules can be obtained under physiological conditions at a spatial resolution
better than that obtainable with light microscopy [182]. No other structural probe can surpass
this performance at the single molecule level. The rapid increase in the number of publications
released each year has firmly established AFM as a major contender in structural biology. This
is almost unparalleled progress if you consider that AFM was only introduced 16 years ago.
1.2.2 Atomic force microscopy
AFM is the most widely used of the SPM techniques. Invented by Binnig et al. [168] in 1986,
it is also conceptually the most straightforward. AFM could be compared to a blind person
scanning the environment with a stick to explore the path ahead. Deflections of the stick are
recorded and used to assemble an image in the brain. In AFM, the sample is scanned with a
cantilever whose deflections are monitored by laser and recorded by a computer, which
generates a 3D image of the sample's surface (Fig. 1.5). The greatest advantage of AFM is its
ability to image the surface of cells and even bio-macromolecules in situ, if not in vivo, which
opens an exciting new approach to visualisation in structural biology. It is not surprising that
AFM has become the focus for many novel biological applications in recently published
studies [183].
Recently, topographs of a-hemolysin packed into supported lipid bilayers were recorded at
1nm lateral resolution and show that a-hemolysin exists as a hexamer when associated with a
lipid bilayer [184]. The functions of the protein complexes were unimpaired, as the
topographs were recorded in physiological buffer by low-force contact. This application was
utilised in another study on the outer membrane of gram-negative bacteria. These membranes
are often assembled from regularly packed protein channels and have been the subject of
extensive electron microscopic analyses. Using AFM, changes in an outer membrane pore of
E. coli (porin OmpF) were recorded [185]. The study showed that pore changes were triggered
by a change in pH from 7 to 3, as well as by an external electric field. Another study has also
imaged gadolinium-induced pore formation on erythrocytes using 1.5% glutaraldehyde in Tris
buffer [186].
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Figure 1.5. Diagram illustrating the atomic force microscope scanning process
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These examples highlight the reliable images of eukaryote and bacterial cells that have
recently been obtained [187,188] in the nanometer range. This opens a new approach to
studying the interaction of antimicrobial peptides with target cell membranes.
We used AFM as a novel approach for studies on antimicrobial peptides and their interaction
with target cell membranes. Methods were developed to image the interaction of antimicrobial
peptides with target membranes. A comparison was made of the structural changes induced by
synthetic magainin (non-toxic) (synthesis and purification described in Chapter 2) and isolated
bee-venom melittin (toxic) on different cell membranes (Chapter 3). Dose response effects
were observed with both biological activity assays and AFM. Specifically, the activity of these
peptides was characterised in terms of lytic activity on eukaryotic cells (goat erythrocytes) and
both lytic activity and inhibition of growth of bacterial cells (E. coli). Furthermore, we suggest
a hypothetical model, based on conclusions drawn from previous model membrane studies
and our AFM results (Chapter 4).
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Chapter 2
Synthesis and purification of magainin 2
2.1 Introduction
Since the turn of the last century, peptide synthesis has been a great challenge to organic
chemists, when the pioneering success of Curtius [1] and later Fischer [2] stimulated new
theories in protein structure [3,4]. By the early 1950s it was realised that other important
biological molecules had simpler amino acid sequences resulting in the subsequent isolation
and synthesis of the first biologically active peptide called oxytocin, a lactogenic nonapeptide
amide hormone [5]. This stimulated a surge of interest in the scientific community resulting in
the synthesis of numerous biologically active peptides. Pharmaceutical companies also
realised the market potential, but classical methods of solution peptide synthesis were hard
pressed to meet the explosive increase in demand. In 1962 R.B. Merrifield proposed a
solution to the problem [6] with a new procedure called solid phase peptide synthesis (SPPS).
The method was initially criticised because of its potential for many side-reactions and
contaminants. However, by 1964 Merrifield had substantially developed the technique [7] to
the extent that he was able to synthesise the naturally occurring nonapeptide bradykinin in
four days (instead of four weeks) and isolated, purified, and fully characterised it in a further
five days. Merrifield's technique was well timed and adopted with enthusiasm by
biochemists, pharmacologists, and others who saw an answer to their pressing need for
synthetic analogues of the many natural peptides being discovered.
Solid phase peptide synthesis has predominant advantages over solution peptide synthesis
because of the simplicity of separation from reagents and solvents by filtration and washing,
as well as the consequent savings in time and labour. Physical losses are also kept to a
minimum, excess reagents can be utilized to drive the reactions to completion, and
subsequently many of the operations are open to automation. This approach does, however,
have its limitations: by-products formed from either incomplete reactions, side-reactions, or
impure reagents will accumulate on the resin during chain assembly and contaminate the final
product. This has serious implications with regard to product purification, because the
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impurities generated are often very similar to the desired peptide and therefore extremely
difficult to separate. The principles of solid phase synthesis are illustrated in Figure 2.1.
The two main techniques used in solid phase peptide synthesis are the Merrifield and the 9-
fluorenylmethoxycarbonyl-based (Fmoc-based) techniques respectively. The principal
features of the Merrifield technique [8-10] are illustrated in Figure 2.2.
x = Temporary amino protecting groups Y' and Y" = Permanent side-chain protecting groups
H 0~Nyo~
R'
dJ
Deprotect primary amino group
Repeat
R'
dJ
Couple
R'
dJ
A = Carboxy activating group
Deprotect primary amino groups
and cleave from resin
Figure 2.1 Principles of SPPS: The carboxyl group of the first C-terminal amino acid
residue is attached with an ester-bond to the linker of the insoluble support. Any
functional amino acid groups must be masked with permanent protecting groups
that are not affected by the reactions conditions used during peptide synthesis.
The temporary protecting groups masking the a-amino groups during the initial
loading of the resin are removed.
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CH
_3_ _J~I (t~~"-/y ~~ resin
Boc protection group 0
2.3
side-chain protecUon group TFA/DCM
Repeat
DIPEAlDCM
Boc·Ala-OH
I) TFA/DCM
II) HF/anlsole
Figure 2.2 Merrifield SPPS: The C-terminal is anchored to the support through the
formation of a benzyl ester with hydroxymethylphenylacetamidomethyl
polystyrene (PAM resin). The tert-butoxycarbonyl (Boe) group is used for
temporary protection of the a-amino group and trifluoroacetic acid (TFA) or
TFA in dichloromethane (DCM) is used to liberate it from the amino acid. The
resulting trifluoroacetate is neutralised prior to coupling using
diisopropylethylamine (DIPEA) in DCM. Coupling is mostly carried out using
pre-formed amino acid symmetrical anhydrides or benzotriazolyl esters in N,
N'-dimethylformamide (DMF) or N-methylpyrrolidone (NMP). The side-
chains are protected using a wide range of benzyl-based protecting groups.
Anhydrous hydrogen fluoride is used for release of the peptide from the resin
and for removal of the side-chain protection groups.
Improvements in the quality of base-resin material, tert-butoxycarbonyl (Boc)-protecting
amino acids, and the introduction of improved hydrogen fluoride (HF) cleavage procedures
has made this technique an extremely powerful tool in the last few years. However, the need
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to use highly toxic liquid HF in a special polytetrafluoroethylene (PTFE)-lined apparatus
has generally deterred most newcomers to the field from using this technique.
Unlike the Merrifield approach that makes use of graduated acidolysis (Fig. 2.2), Fmoc-based
SPPS (Fig. 2.3), developed in the late 1970s [11] is based on an orthogonal protecting group
strategy. A base labile N-Fmoc group was used for protection of the a-amino group and acid-
labile side-chain protection groups and resin-linkage agents. Since removal of the temporary
and permanent protection is effected by completely different chemical mechanisms, side-
chain protecting groups and linkage agents can be employed that are removed under
considerably milder conditions than those used in the Merrifield method. T-butyl- and trityl-
based side-chain protection and alkoxybenzyl-based linkers are used, as they can be removed
using TFA. This reagent is an excellent solvent for peptides. It can be used with standard
laboratory glassware and being volatile, is readily removed by evaporation. The results of an
unprecedented survey paper [12] by the Association of Biomolecular Research Facilities
highlighted the superiority of the Fmoc strategy, confirming its undoubted status as the most
popular method for SPPS and a well-established method in our laboratory. The principle
features of the Fmoc-based SPPS [13,14] are illustrated in Figure 2.3.
We used the Fmoc-based SPPS to synthesise Magainin 2 (Mr=2466.93;
GIGKFLHSAKKFGKAFVGEIMNS). We chose this peptide because of its unique and
well-documented mechanism of action, as well as its broad-spectrum of activity and lack of
toxicity [15,16]. Magainin's structural parameters do not favour haemolytic interactions, as
the positive charges are spread over the whole peptide and the hydrophobicity and
hydrophobic moment are moderate [17]. However, electrostatic interactions do promote
antimicrobial activity towards gram-negative and gram-positive bacteria [18,19].
We used melittin purchased from Sigma (Mr 2846.50;
GIGAVLKVLTTGLPALISWIKRKRQQ-amide) as a control peptide during our AFM
studies. We chose this peptide because of its lack of selectivity between mammalian and
bacterial cells [20]. Melittin's structural parameters favour haemolytic activity, as the N-
terminal is strongly hydrophobic with a large hydrophobic angle, promoting deep penetration
into the hydrophobic membrane surface, which might favour the association of membrane
bound peptides to form pores [17,21]. In addition, it has an amphipathic highly positive C-
terminal sequence, which contributes to its activity against gram-positive and gram-negative
bacteria [17].
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Fmoc protection group
Side-chain
protection group
Plperldlne/DMF
Repeat
Fmoc-Ala I HOBt I DIPEA
I) TFA/DCM
II) TFAI H20
Figure 2,3 Fmoc-based SPPS: The C-terminal of the first residue is anchored to a TFA-
labile linkage agent. The side-chains are protected with TFA-labile protecting
groups, The temporary .i\P-Fmoc protecting group is removed with 20%
piperidine in DMF, Coupling is typically carried out in DMF or NMP with pre-
formed active esters or using activation reagents that generate benzotriazolyl
esters. Cleavage of side-chain protecting groups and the peptide from the resin is
achieved with 95% TFA.
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2.2 Materials
2.2.1 General reagents and solvents
N, N'-dimethylformamide (DMF; 99.5%), ethyl acetate (99.5%), glacial acetic acid (99.8%),
sodium carbonate (anhydrous), phosphorus-pentoxide, molecular sieve (4 Á beads
approximately 3.2 mm) and self-indicating silica gel were purchased from Saarchem
(Krugersdorp, South Africa). Diethyl ether (99.5%), n-hexane (99.8%), tert-amylalcohol
(>99%), ethanol (99.8%), piperidine (98%), pyridine (99.5 %), trifluoroacetic acid (TFA;
>98% and 99.5%), potassium cyanide (KCN), ninhydrin, I-fluoro-2,4-dinitrobenzene
(FDNB) and phenol were purchased from Merck (Darmstadt, Germany). Piperidine (99%),
pyridine (99.9%) and TFA (>98%) were also purchased from Sigma (Steinheim, Germany).
Thioanisol and 1, 2-ethanedithiol were from Fluka (Steinheim, Germany). Nitrogen gas was
provided by Afrox, South Africa.
2.2.2 Derivatives, catalysts and resins for peptide synthesis
Pepsyn KA-resin (0.15 & 0.2 meq/g), Fmoc-L-Ala-OPfpl, Fmoc-L-Gly-OPfp, Tboc-Gly-OH,
Fmoc-L-His-(Boc)-OH, Fmoc-L-Ile-OH, Fmoc-L-Ile-Opfp, Fmoc-L-Leu-OPfp, Fmoc-L-Leu-
OH Fmoc-L-Lys-OPfp Fmoc-L-Met-OH Fmoc-L-Phe-OH Fmoc-L-Phe-OPfp and Fmoc-, , , , ,
L-Val-OH were from Milligen-Millipore (Milford, USA). Fmoc-L-Asn-OPfp, Fmoc-L-Asn-
(Mbh)-OH, Fmoc-Glu-(tBu)-OH, Fmoc-L-Gly-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys-(Boc)-
OH, Fmoc-L-Ser-(tBu)-OH, Fmoc-pentafluorophenol, and N, N'-diisopropylethyl amine
(DIPEA) were purchased from Sigma (Steinheim, Germany). Benzotriazol-l-yl-oxy-tris-
pyrrolidinophosphonium hexafluorophosphate (PyBOp®) and l-hydroxybenzotriazole
(HOBt) were supplied by Calbiochem-Novabiochem Co. (La Jolla, USA).
2.2.3 Reagents and solvents for chromatography
Methanol (HPLC-grade, UV cut-off 205 nm), acetonitrile (HPLC-grade, UV cut-off 190 nm)
were from Romil LTD (Cambridge, UK). Nova-Pak analytical HPLC columns, 0.45 micron
1 OPfi>= pentafluorophenyl ester; activated a-carbonyl group
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HY membrane filters were provided by Waters-Millipore (Milford, USA). Polygosil (CI8,
60 A, irregular particles) packing material was supplied by Macherey-Nagel (Dillen,
Germany). Sephadex GlO was from Pharmacia Fine Chemicals (Uppsala, Sweden), and CM-
Separose (CL-6B) was purchased from Sigma, USA. Analytical grade water was prepared by
filtering glass-distilled water through a Millipore Milli Q®water purification system.
2.2.4 Drying and storage of reagents and products
Fmoc-amino acids and peptide synthesis resins were stored at 4°C in desiccators with silica
gel as drying agent. The FDNB was stored at <10°C and the PYBOp® and the HOBt at
-20°C, both with silica gel (with indicator) as drying agent. Before use, amino acid
derivatives, resins, PyBOp® and HOBt were dried overnight under high vacuum, with
phosphorous-pentoxide as drying agent. The freshly distilled DMF was stored over molecular
sieve (4 A beads approximately 3.2 mm) at room temperature. Peptides were stored at room
temperature, under vacuum in a desiccator, with silica gel as drying agent. All other reagents
were stored at room temperature.
Great care was taken to avoid detergent contamination of glassware, because this type of
contamination of a peptide preparation could influence its bioactivity. Detergent
contamination could easily be detected with electro spray ionisation mass spectrometry (ESI-
MS) as most laboratory detergents contain highly charged compounds. The glassware,
returned from the regular wash, was rinsed three times with distilled water, three times with
60% ethanol and then rinsed three times with analytical grade water. It was placed in an oven
to dry at temperature ranging between 110°C and 140°C. Bottles for amino acid derivatives
and purified peptides were also prepared in the same way and then pyrolised at 565-570°C for
2 hours.
2.3 Methods
All the SPPS methods are standard peptide synthesis procedures refined or developed in the
BIOPEP laboratory [23]. Variations to these standard protocols have been included here.
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2.3.1 Preparation of solvents
2.3.1.1 Distillation ofN,N' -dimethylformamide
DMF is an excellent solvent both for protected amino acids derivatives and for most reagents
used in peptide synthesis. It is the principal solvent used in Fmoc-polyamide solid phase
peptide synthesis and it is imperative that it is always freshly distilled and highly pure. Impure
DMF is often contaminated with secondary amines and H20, which can react with the Fmoc-
and active ester groups of the peptide. DMF reacts with water to form dimethyl amine and
formic acid [22,23]. DMF was shaken up with 10-20 gIL dry potassium hydroxide pellets to
remove residual water, or stored for at least one week on activated molecular sieve (4Á beads
approximately 3.2mm). Impurities such as volatile secondary amines were removed by
fractional distillation under vacuum (high vacuum; 5-7mm Hg) and dry nitrogen bleed. The
first 10-15% of the distillate was discarded and the constant boiling fraction was collected.
Only the DMF that passed the Sanger's test for amines was used (see below), otherwise it was
redistilled.
2.3.1.2 Sanger's test for amines
Secondary amines in DMF can cleave the base-labile Fmoc-group from the N-terminus of the
peptide or from the Fmoc-amino acid, causing unwanted polymerisation during peptide chain
elongation. Sanger's reagent is used to test for the presence of amines and determine the
quality of DMF prior to use [10]. It was performed by mixing equal volumes of FDNB (1.0
mg/mL in 95% ethanol) and DMF at room temperature for 30 minutes and subsequently
determining the absorbance of the reaction mixture at 381 nm. FDNB (0.5 mg/rnL in 95%
ethanol) was used as a blank and measured in the region of 0.2 absorbance units. DMF with
an absorbance of 0.025-0.05 units higher than the blank was used in the coupling procedure as
well as in the washing steps prior to coupling procedure. Lower quality DMF with an
absorbance of 0.05-0.08 units higher than the blank was used for the other washing steps.
To ensure the removal of all traces of piperidine used in the deblocking steps during the
peptide synthesis protocol, the Sanger test was also performed on DMF samples from the
final washing step, before the coupling of the next amino acid. The samples were incubated
with an equal volume of FDNB (0.5 mg/mL in 95% ethanol) for 2-3 minutes, compared to a
blank solution (DMFIFDNB; 1:1), and accepted as piperidine-free if they were no more than
0.01 absorbance units higher than the blank.
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2.3.1.3 Distillation of piperidine and pyridine
Piperidine was purified by distillation over dry potassium hydroxide (10-20 gIL) and a dry
nitrogen bleed at atmospheric pressure. The first 10-15% of the distillate was discarded and
the constant boiling fraction (105°C) was collected. The distilled piperidine was stored in dark
bottles and used within three months [22]. Pyridine for use in the Kaiser-ninhydrin test was
distilled in the same way [23].
2.3.1.4 Distillation ofN,N' -diisopropylethyl amine
N, N'-diisopropylethyl amine was initially distilled over ninhydrin (1-2 gIL) and then
redistilled over dry potassium hydroxide pellets (5-10 gIL). Distillation was performed at
atmospheric pressure under dry nitrogen bleed. A small forerun was discarded, and the
constant boiling fraction with boiling point between 125-127°C was collected. Small volumes
(±4mL) were aliquoted into amber vials, flushed with dry N2, sealed and stored at -20°C.
Small volumes were distilled because of the instability of the reagent [24].
2.3.2 Preparation and quality control of the amino acid derivatives
2.3.2.1 Melting Point Determination
The melting point of all derivatives and catalysts (PyBOp®, HOBt) were determined before
peptide synthesis. A small amount of derivative was placed in the bottom of a capillary tube
and the melting point determined using a Gallenkamp melting point apparatus. The amino
acid derivatives and catalysts were only used in peptide synthesis if their melting points were
3-5°C higher or lower than their literature values [13].
2.3.2.2 Purification of Fmoc amino acid derivatives
Amino acid derivatives showing positive Kaiser tests (see 2.3.3.4) or incorrect melting points
were purified and reassessed prior to use in a synthesis. Fmoc-amino acids without acid labile
side-chain protection were suspended in 1% acetic acid (0.1% acetic acid, if an acid labile
side chain protection group was present) and the undissolved Fmoc-amino acid derivative was
collected by filtration. The precipitate was then washed with water, ice-cold methanol, ethyl
acetate, and diethyl ether and dried thoroughly under vacuum. If the Kaiser test remained
positive, the derivative was re-crystallised from hexane/ethyl acetate. The OPfp activated
Fmoc amino acid derivatives were re-crystallised from hexane and/or washed with ice-cold
ethyl acetate and n-hexane.
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Table 2.1 Operations for one cycle of the peptide synthesis procedure (Table reproduced
with kind permission from M. Rautenbach [23])
Synthesis Step Time Volume Monitoring Comment
1. Swelling of resin 20 min. 4 bed volumes Bed volume=
5mL/gram resin
2. Anchoring of first amino 2 hours <1/2 bed volume Fmoc-test Refer to section
acid via activated 2.3.3.1 and 2.3.3.5
Fmoc-amino acid to
resin
3. DMFwash Minimum of 6
x 3 bed volumes
4. Resin sample A Kaiser test (2.3.3.4) If test is positive,
extend or repeat
coupling step in
elongation.
5. Removal of Fmoc 30 min. 3 bed volumes Absorbance at 290 Refer to sections
groupe deblocking) with 2.3.3.3 &t 2.3.3.5
20% piperidine in
DMF.
6. DMFwash Minimum of 10
x 3 bed volumes
7. DMF wash sample 0.5mL Sanger test (2.3.1.2) Wash until test is
negative
8. Resin sample B Kaiser test (2.3.3.4) If test is negative,
repeat deblocking
9. Coupling of next amino 60 min. <1/2 bed volume Refer to sections
acid via activated 2.3.3.1 &t 2.3.3.2
Fmoc-amino acid
Repeat steps 3, 4
&t 9 if necessary
10. Repeat steps 3-8
Il. Repeat steps 9 s. 10 for
a-amino acids in sequence
12. Washing &t drying of Refer to 2.3.3.3
resin
13. Liberation of peptide Refert02.3.3.6
acid from resin
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2.3.3 Synthesis of the peptides
The peptides were synthesised at room temperature (20-25°C) according to the Fmoc-based
protocol using a shake flask procedure [23]. Two full-length syntheses and one extension of a
resin-bound magainin without its four N-terminal residues (magainin 2 N19) were performed.
The protocol for a complete cycle of operations including washing, coupling, deblocking, and
sample steps is set out in Table 2.1.
2.3.3.1 Coupling of the first amino acid
Pepsyn KA-resin (capacity of 0.15 or 0.2 milli-equivalents per gram resin) was used in the
syntheses, to which the first amino acid was coupled via the PyBOp® method (described
next). The coupling efficiency was evaluated using the Fmoc-test (section 2.3.3.5), and the
coupling step was repeated until the resin was completely saturated'. Prior to synthesis, the
resin was swollen for approximately 20 minutes in high purity DMF (20 mUg).
2.3.3.2 Elongation of the peptide chain
The reagent quantities used during the elongation steps were calculated from the resm
capacity of 0.15 or 0.2 milli-equivalents per gram of dry resin. The OPfp activated derivatives
of the Fmoc-amino acids were coupled with HOBt as a catalyst and trapping agent [25,26]
using a 3-7 fold molar excess for each. Fmoc-amino acids were coupled using the PyBOp®
method in the following manner: a 3-7 fold molar excess of the protected amino acid and
HOBt, were each dissolved in a minimum volume ofDMF (0.5-1.0 mL), combined and added
to the resin. PyBOp® was subsequently mixed at 3-7 fold molar excess with a 6-14 fold molar
excess of DIPEA, both in a minimum volume of DMF (0.5-1.0 mL) and the combination
added to the resin [23,27]. Complete acylation was obtained after 60-120 minutes as
determined with the Kaiser test and/or Fmoc-test.
2.3.3.3 Removal of the Fmoc-group from the attached amino acid
Once the coupling was completed, as shown by a negative Kaiser test, the resin was washed
to remove excess active amino acid derivative and catalyst. The Fmoc-group was
subsequently removed from the coupled amino acid by incubation with at least three bed
volumes of piperidine (20% DMF) for 30 minutes. After each deblocking step, the absorbance
2 It should be noted that the first amino acid coupled to the resin is the last amino acid (S23) in the magainin
peptide sequence.
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was recorded at 290nm. Each absorbance value was compared to the absorbance values
obtained from previous deblocking steps to show the extent of deblocking. After the
piperidine was removed, the resin was thoroughly washed with DMF until an acceptable
Sanger test was obtained (section 2.3.1.2).
2.3.3.4 The Kaiser Test
The Kaiser test is specific to primary amino groups [28] and consists of three solutions: (a)
500mg ninhydrin in IOmL 95% ethanol, (b) 40g phenol in IOmL 95% ethanol and (c) 2mL
O.OOIMKCN solution diluted to 100mL with distilled pyridine. The Kaiser test was used
during peptide synthesis to evaluate the deblocking process, as well as the coupling of each
amino acid. The test proceeds as follows: 4-5 resin beads were dried using diethyl ether and 3-
5 drops of each solution was then added to the beads. This was incubated for 1-10 minutes in
a water bath at 80-90°C and the colour of the resin beads and the reaction mixture was
subsequently evaluated using a magnified eyepiece. A positive result, as expected after
deblocking, caused the beads to change colour varying from light to dark blue depending on
the amino acid. Exceptions were found with G (beads changed to a yellow-brown colour), S
and N (beads changed to a brown/orange colour). A negative result, as expected after
coupling, showed no change in the colour of the beads or reaction mixture.
Quality control of the Fmoc-amino acid derivatives was also done using the Kaiser test. Five
milligrams of the dried derivative was dissolved in IOOIlIDMF, after which IOOIlIof each of
the Kaiser test solutions were added. Colours were evaluated after five minutes incubation at
90°C. To determine the extent of contamination of a derivative, its Kaiser test result was
compared to a standardised colour chart.
2.3.3.5 The Fmoc-test
To evaluate the coupling of an Fmoc-amino acid, and specifically the coupling of the first
amino acid, the UV absorbance character of the liberated Fmoc-fulveen group was exploited
[25,29]. An analytical test was developed in our laboratory [30-32] whereby the concentration
of the Fmoc-groups released, subsequent to the deblocking step, could be used to calculate the
percentage of coupling. The linear relationship between the percentage liberated Fmoc and the
absorbance at 290 nm was as follows:
Á290 = 0.002848 x % liberated Fmoc-groups - 0.009975
This test proved to be useful as an alternative to amino acid analysis, a time consuming
procedure. To evaluate a coupling step, 10-15mg of resin was removed, washed with DMF
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and diethyl ether and dried for 60 minutes. The resin was then analytically weighed and
deblocked with a volume of 20% piperidine in DMF that was equivalent to 20mL per
O.1mmol of expected Fmoc-groups. After deblocking, a 100 times dilution (in triplicate
determinations) was made of the deblocking mixture and the absorbance determined at
290nm. The absorbance values were entered into the previously determined standard curve
equation and the percentage coupling determined.
2.3.3.6 Removal of the completed peptide from the resin
After the deprotection and DMF wash of the final amino acid, the resin was washed with t-
amyl alcohol, glacial acetic acid, again with t-amyl alcohol, and finally dried with diethyl
ether [24,25,32]. The peptides were cleaved from the resin using reagent K (82.5% TFA, 5%
phenol, 5% H20, 5% thioanisol, and 2.5% 1,2-ethanedithiol) [33] and separated from the resin
by filtration. The resin was washed with TFA, glacial acetic acid, and analytical grade H20
and the filtrate collected. The resin was subsequently washed with ether and vacuum dried.
The filtrates, containing peptide, were concentrated under vacuum using a Buchi Rotavapor at
45°C. The peptide concentrate was then dissolved in 50mL analytical grade water and
extracted three times with 50mL diethyl ether. The combined ether fractions were then
washed with 50mL analytical grade water to recover any peptide in the ether. The combined
aqueous fractions were freeze-dried.
2.3.4 Purification of the peptides
2.3.4.1. Gel-permeation chromatography
The peptides were initially purified by Sephadex GlO gel permeation chromatography using
analytical grade water as eluant. Freeze-dried crude peptide preparations were dissolved in 2-
3 mL of water, equivalent to 1.7-2.5 % of the column bedvolume (39 x 2cm; 122.5 crrr'), their
absorbance measured at 230nm and 257nm3 and then loaded (10mg/mL) onto the Sephadex
GlO column. Flow rates were 10-14 mL/hour and the major absorbing fractions were
collected and freeze-dried.
3 Phenylalanine forms part of the magainin peptide sequence, and absorbs maximally at 257 nm.
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2.3.4.2 Cation exchange chromatography
A CM-Sepharose CL-6B column utilising a 0.35-0.45M ammonium acetate (pH. 6.00)
gradient was used for further purification of the peptides.
The column was regenerated by running a linear 0.35 - 0.45 M ammonium acetate (pH. 6.00)
gradient, followed by equilibration with three bedvolumes of 0.35M ammonium acetate (pH.
6.00). Freeze dried peptide preparations were dissolved in 2-2.3 mL of equilibration buffer
equivalent to 10-12% of the column bed volume (11 x 1.5 cm; 20.32 cnr'), and loaded onto
the column (10-12mglmL). The flow rate was ±14mL/hour. Elution was started with the
equilibration buffer, and after an hour (±14mL eluant) a linear gradient was introduced with
the highest concentration of ammonium acetate (0.45M; pH.6.00) as the final concentration.
The eluted fractions were monitored at 230nm and 257nm and the major absorbing fractions
were collected and freeze-dried.
2.3.4.3 Semi-preparative high performance liquid chromatography
Semi-preparative HPLC was used as a final purification step in order to achieve magainin 2 of
high purity. Peptide samples (5mglmL) were dissolved in 50% acetonitrile in analytical grade
water. All samples were then centrifuged for 5 minutes, using aSTRATAGENE Picofuge™,
to remove particulate. Sample volumes loaded varied between 50-150j.!L. The HPLC system
consisted of the following components: two Waters 510 pumps, a Waters Model440 detector
(monitoring at 254nm), a WISP 712 sample processor, a controller system with MAXIMA
software, and a semi-preparative CIS Polygosil HPLC column (irregular particle size, 60 A
pore size, 8 x 250 mm). A linear gradient (3 mL/min flow rate) was created using eluant A
(0.1% TFA) and eluant B (90% acetonitrile and 10% eluant A) as shown in Table 2.2 [32].
Peptide fractions were collected, and freeze-dried for further analysis.
2.3.5 Analysis of purified peptides
2.3.5.1 Analytical high performance liquid chromatography
Analytical reverse phase high performance liquid chromatography was used to determine the
purity of the synthetic peptides. A CISNova-Pak HPLC column (3.9 x 150mm) was used with
the system described under section 2.3.4.3. The chromatography was monitored at 254nm and
the same gradient was employed as for preparative HPLC, but the flow rate was reduced to
1.0mL/min (Table 2.2), loading 20j.!L samples at 2 mglmL (Table 2.2).
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Table 2.2 Gradient program used for the HPLC of the peptide preparations
Flow rate; preparative Flow rate; analytical
Time (min) HPLC (mL/min) HPLC (mL/min) %A %B
0 3.0 1.0 80 20
0.5 3.0 1.0 80 20
13 3.0 1.0 15 85
13.1 3.0 1.0 0 100
14 3.0 1.0 0 100
20 3.0 1.0 80 20
25 3.0 1.0 80 20
2.3.5.2 Mass spectrometry
A Micromass Quattro triple quadropole mass spectrometer, fitted with an electro spray
ionisation source, was used for electro spray ionisation mass spectrometry (ESI-MS). Peptide
samples (0.2-0.3 mg/mL) were dissolved in 50% acetonitrile in analytical grade water
modified with 0.01 % TFA. Ten !J.I of the sample was introduced into the ESI-MS at
20!J.Llminute using a Rheodyne injector valve. The applied capillary voltage was 3.5 kV and a
cone voltage of 50 V with the skimmer lens offset at 5 V was used in all the analysis. The
source temperature was 80°C. Data was acquired in the positive mode for these cationic
peptides, scanning the first analyser (MSl) through a m/z (molecular mass to charge ratio) of
between 100 and 1500 at a scan rate of 5 sec/scan atomic mass units/second. Combining a
number of scans across the elution peak and subtracting the background produced
representative spectra.
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2.4 Results and Discussion
2.4.1 Synthesis 1of Magainin 2
2.4.1.1 Coupling of the first amino acid
Serine (S23), the last amino acid in the magainin 2 sequence", was esterfied to the 4-
hydroxymethylbenzoic acid linker of the 0.2 mmol Pepsyn KA resin in a previous study
performed by Gertrude Lourens. It came to our attention that some of the Fmoc-groups were
liberated after coupling, due to erroneous short-term exposure to piperidine. It had been
determined that only 75% of the S23 N-terminal primary amino groups were still Fmoc-
protected. To ensure that the resin was fully saturated with the first amino acid, the
unprotected amine groups were blocked again by incubating the S23-resin with an excess of
Fmoc-OPfp and HOBt for 90 minutes using freshly distilled DMF as solvent. It was
confirmed that the exposed N-terminal primary amino groups of S23 were re-protected with a
negative Kaiser test and a 103% yield according to the analytical Fmoc test, which has an
accuracy of ±5%.
2.4.1.2 Elongation of the peptide chain
Asparagine (N22) was the second amino to be coupled and a negative Kaiser test was
obtained after 90 minutes of incubation with the resin. The deblocking procedure for N22
appeared problematic with a negative Kaiser test after 30 minutes, which indicated that the
Fmoc-groups had not been liberated from the N-terminal of the peptide chain. The resin was
deblocked for an additional 30 minutes before complete deprotection and a positive Kaiser
test was obtained. Although the absorbance of the liberated Fmoc-group, at 290nm, had
dropped by 12% we continued with the coupling of methionine (M21). The resin showed a
negative Kaiser test after 90 minutes of coupling, but the Fmoc-absorbance subsequently
dropped by another 43%. The resin was again deblocked for another 30 minutes, but no or
little additional Fmoc-groups were liberated. Although the synthesis had been compromised,
the Fmoc group of M21 was recoupled using fresh peptide to reassess coupling percentage.
The Fmoc-absorbance was still 17% lower than that obtained for N22. During the rest of the
4 Amino acid derivatives for the synthesis of the magainin 2 sequence (M23) will be annotated as follows
throughout chapter:
GI 12G3 K4 F5 L6 H7 88 A9 KlO KIl Fl2 Gl3 Kl4 Al5 Fl6 Vl7 Gl8 El9 120M21 N22 823
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synthesis constant Fmoc liberation and negative Kaiser tests were obtained for all the
remaining couplings, using a three-fold excess concentration of amino acid derivative (see
2.3.3.2).
2.4.1.3 Purification and analysis of synthesis 1 peptide products
Low molecular mass impurities and solvents that accumulated during synthesis and peptide
cleavage were separated from the peptide using Sephadex GlO gel-permeation
chromatography (Fig. 2.4). The major absorbing fraction (Ve = 51 ml; Ve is the elution
volume) that eluted from the Sephadex G10 column was conservatively pooled into fractions
and analysed using ESI-MS (Fig 2.5).
The ESI-MS results indicated that Magainin 2 (M23) had been synthesised (Fig. 2.5). The
correct mlz (molecular mass/charge ratio) in multiply charge forms were present, namely
617.29 ([M23+4Ht+), 823.3 ([M23+3H]3+), and 1234.53 ([M23+2H]2+). The fractions were,
however, contaminated with oxididated side-products 828.67 ([M23+0+3H]3+) and 3
additional triply charged deletion analogues (mlz= 756.22, 706.33, and 668.29). The major
contaminant appeared to be as a result of the exclusion ofN22 and S23 with an m/z of 756.22
([M23-N22-S23+3H]3+). The early contamination and subsequent dramatic loss in yield
experienced with the N22 exclusion is possibly the result of a common side chain reaction
that occurs during Asn-Ser sequence peptides. The long exposure to piperidine together with
the possible liberation of the tBu and trityl side-chain protection groups of S23 and N22
respectively can result in aspartimide formation on N22 [24]. The reaction involves the attack
of the nitrogen on the side-chain ester of N22 and the subsequent formation of an amide (Fig.
2.6). This intermediate can suffer a number of fates resulting in dramatic loss in peptide yield.
This in turn could be responsible for the difficulty experienced with the coupling of M21.
Due to the low crude yield obtained, it was decided re-synthesise the peptide implementing
additional controls to solvents and derivatives to reduce contamination and product loss. The
concentration of amino acid derivatives was increased from a three fold to a 5-7 fold excess to
drive the reactions to completion.
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Figure 2.4 An example of the Sephadex GlO chromatography elution profile generated by
the crude magainin 2 peptide during synthesis 1. The crude peptide mass was 30
mg. Peak B contained the main peptide fraction (ESI-MS: figure 2.5), whereas
peak A and C contained the main deletion analogue fractions.
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Figure 2.5 Positive mode ESI-MS of fraction B (see figure 2.4) of the peptide mixture
collected after Sephadex GlO chromatography: A representing magainin 2, B is
its oxidized side-product, and C-E are the deletion analogues.
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Figure 2.6 Possible aspartimide formation on N22 during synthesis 1 : the five-membered
imide can undergo ring opening during Fmoc-removal and later hydrolyse in
solution to form the corresponding a- and l3-apartyl peptides.
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2.4.2 Synthesis 2 ofMagainin 2
2.4.2.1 Coupling of the first amino acid
Pepsyn KA resin (O.15mmol) was incubated with the first amino acid derivative, Fmoc-
Serine(tBu)-OH (S23) for 24 hours and the resultant Fmoc test indicated an 83% coupling.
The resin was washed and re-incubated with fresh derivative for a further 24 hours, however
coupling only increased to 87%, probably due to steric hindering. To insure that no deletion
analogues were formed as experienced in synthesis 1, we blocked the remaining OH groups of
the resin with the smaller tBoc-Gly-OH. The acid labile tBoc protection group of Gly would
remain attached during the rest of the synthesis because of the mild reaction conditions of the
Fmoc method and the liberated Gly would be easy to purify from our main peptide product.
To ascertain whether the tBoc-Gly-OH coupling and blocking was completed we performed
three additional Fmoc-tests to compare with the original Fmoc-test of 87% (see Figure 2.7a).
The first Fmoc-test was a positive control, coupling Fmoc-Gly-OH to an S23-resin test
sample prior to incubation with tBoc-Gly-OH. The result showed a 98% coupling indicating
that there were open OH groups on the resin that required protection. The second Fmoc-test
was after the incubation oftBoc-Gly-OH with the S23-resin and showed a coupling of 87% as
expected. The third Fmoc-test was taken on a tBoc-Gly-S23-resin test sample that was
incubated with Fmoc-Gly-OH and also gave an 87% coupling, confirming that the tBoc-Gly-
OH had blocked all the remaining open OH groups on the resin and that the next amino acid
could be coupled.
2.4.2.2 Elongation of the peptide
Stringent Kaiser tests and melting point tests were performed on all amino acid derivatives
and activating agents before coupling commenced, using a 5-7 times excess concentration.
Satisfactory Kaiser tests and were obtained for all couplings, although some of the Fmoc
liberations over the last third of the peptide (S8-G 1) appeared problematic (Fig. 2.7b). The
peptide was successfully cleaved from the resin.
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Frroo-Ser Frroo-Ser
FrrooGy
FrrooGy
1 2nd Frroc Test (1J701o) 1
1 1st Frroc Test (98%) 1
Frroo-Ser
13rd Frroc Test (lJ7O/o) 1
Figure 2. 7a A flow diagram illustrating the test procedure followed to ascertain
whether the tBoc-Gly-OH had completely blocked all open binding sites
on the resin beads during synthesis 2.
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Figure 2. 7b Fmoc absorbance measurements after deblocking of each amino acid coupling
during synthesis 2
2.4.2.3 Purification and analysis of synthesis 2 peptide products
Low molecular mass impurities were removed using gel-permeation chromatography (Fig.
2.8). A major absorbing fraction (Ve = 51 mL) was eluted from the Sephadex GlO column
and was conservatively pooled and analysed using ESI-MS (Fig. 2.9). The ESI-MS results
showed that the major peptide fractions were still contaminated with a Met-oxidised side-
product, an insertion analogue (M23+G1/G3) and a deletion analogue (M23-S8-G3-G1).
We decided to attempt purify both the oxidised side-product and magainin 2 from the
insertion and deletion analogues for later analysis. A sample was chromatographed on a CM
Sepharose CL-6B cation-exchange column using an optimised linear 0.35-0.45M ammonium
acetate (PH6) gradient. Two major absorbing fractions eluted at 25mL (0.364M) and 39mL
(0.376M) respectively (Fig. 2.10). We tested each individual fraction collected with ESI-MS
before pooling the fractions together. Unfortunately the results indicated that neither the
insertion or deletion analogues nor the oxidative side-product had separated from Magainin 2
(Fig. 2.11). This indicated that there was no discernible difference in charge between the
products, which lead us to attempt purification based on their polarity differences using
HPLC. Analytical HPLC was used to optimise a gradient that would best suit the separation
of the contaminants from magainin 2. We used the optimised gradient for semi-preparative
HPLC (Fig. 2.12) and separated the oxidised side-product and the insertion analogue (Fig.
2.13; ESI-MS shown) from magainin 2 (Fig. 2.13; ESI-MS shown) but were still unable to
separate the deletion analogue.
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Figure 2.8 An example of the Sephadex GlO chromatography elution profile generated by the
crude magainin 2 peptide during synthesis 2. The crude peptide mass was 30 mg.
Peak A contained the main peptide fraction, which was analysed using ESI-MS (see
figure 2.9), whereas Peak B contained the major deletion analogue fraction.
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Figure 2.9 Positive mode ESI-MS of peak A (see Figure 2.8) of the peptide mixture collected
after Sephadex GlO chromatography: A representing magainin 2, B is its oxidised
side-product, C is an insertion analogue, D is a deletion analogue, and E is its
oxidised side-product.
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Figure 2.10 CM-Sepharose CL-6B cation exchange chromatography of peak A (see
figure 2.8 and 2.9) during synthesis 2. The main peptide fraction IS
indicated by A, which was analysed using ESI-MS (see figure 2.11).
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Figure 2.11 Positive mode ESI-MS of fraction A (see Figure 2.10) of the peptide
mixture collected after CM-Sepharose CL-6B cation exchange
chromatography indicating the unsuccessful separation of magainin 2
from its oxidised side-product, the minor insertion analogue, and the
deletion analoguewith its oxidised side-product.
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Figure 2.12 A semi-preparative HPLC chromatogram of peak A (see figure 2.8), with the
dashed line representing the respective fractions collected. The gradient was
developed over 13.1 minutes with 0.1% TFA in water as solvent A and
acetonitrile with 10% A as solvent B with a flow rate of 3 mL/min.
Although the problems experienced in synthesis 1 were successfully solved a new problem
was experienced. From an analysis of the ESI-MS results (Fig. 2.9) and the absorbance
measurements after Fmoc removal (Fig 2.7b) obtained during coupling it became evident that
the major reason for this new contamination was possibly due to molecular crowding, caused
by using a five- to seven-fold excess concentration of incubated amino acid per coupling,
instead of the recommended three-fold excess, resulting in the M23-S8-G3-G 1 deletion
analogue and the M23+GlIG3 insertion analogue (calculated using ESI-MS firm spectral
data). Molecular crowding typically occurs with growing peptide chains because of steric
crowding and intersite side-reactions. Furthermore, this leads to incomplete solvation of the
peptide-resin complex, sudden shrinkage of the gel matrix, and reduced reagent penetration
ultimately resulting in failure of the acylation reaction [24]. It resulted in deletion and
insertion analogues that could not be purified from the main product. To solve the
overcrowding problem we commenced a third synthesis with a resin-bound magainin 2 Nl9
using the recommended three-fold excess.
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Figure 2.13 Positive mode ESI-MS of the HPLC separation (see Figure 2.12) ofmagainin 2
and its deletion analogue (top) from the oxidised magainin 2 and insertion
analogue (bottom): A representing magainin 2, B is its oxidised side-product, C
is the insertion analogue, D is a deletion analogue, and E is its oxidised side-
product.
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2.4.3 Synthesis 3 of Magainin 2fromMagainin 2N19
Due to time constraints Magainin 2 N19 was used for the final synthesis.
2.4.3.1 Elongation of the peptide
Magainin 2 N19 on Pepsyn KA; 0.2 mmol, graciously donated by E.A. du Toit, was extended
with K4, G3, 12 and G1. Using a three-fold excess of the activated Fmoc-amino acids,
satisfactory Kaiser tests were obtained for all four couplings and the peptide was successfully
cleaved from the resin.
2.4.3.2 Purification and analysis of synthesis 3 peptide products
Low molecular mass impurities that accumulated during peptide synthesis and cleavage were
removed using gel-permeation chromatography (Fig. 2.14). The Sephadex GlO column
eluted a major peptide fraction at a Ve of 48rnL that was conservatively pooled into fractions
and analysed using ESI-MS.
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Figure 2.14 An example of the Sephadex GlO chromatography elution profile generated by
the crude magainin 2 peptide during synthesis 3. The crude peptide mass was
30 mg. Peak A contained the main peptide fraction, which was analysed using
ESI-MS (see figure 2.15).
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Figure 2.15 Positive mode ESI-MS of the Sephadex G-10 separation (see Figure 2.14):
A representing magainin 2 and B its oxidative side-product.
These results showed that magainin 2 had been successfully synthesised without deletion
analogues, however the fractions were still contaminated with methionine sulphoxide (Met-
oxidised side-product) (Fig. 2.15). During the TFA cleavage process, highly reactive cationic
species are generated from the protecting groups and resin linkers which can, unless trapped,
react with and modify, those amino acids containing electron-rich functional groups such as
tyrosine, tryptophan, methionine and cysteine [24]. For this reason various nucleophylic
reagents, known as scavengers, are added to TFA to quench these ions. Subsequently, Met-
oxidation is normally suppressed by thioanisole, and 1,2-ethanedithiol present in the reagent
K cleavage cocktail. However, an explanation may be that the scavengers were degraded
resulting in the oxidised side-product. (Fig. 2.16).
oxidation
""'8==0
)va
Figure 2.16 Sulphoxide formation on the methyl group (M21) of magainin 2.
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Although the oxidised side-product could be reduced [11] we decided to purify this side-
product for later analysis. Semi-preparative HPLC, based on the gradient optimisation of
synthesis 2, (Fig. 2.17) was used to separate the oxidated side-product from magainin 2.
Semi-preparative HPLC (Fig. 2.18) and ESI-MS (Fig. 2.19) revealed a highly purified
magainin 2 with the correct multiple charged species with mlz 411.92 ([M23+6H]6+), mlz
494.14 ([M23+5H]5+), mlz 617.3 ([M23+4H]4+), mlz 822.74 ([M23+3H]3+), and m/z 1233.80
([M23+2H]2+).
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Figure 2.17 A semi-preparative HPLC chromatogram of peak A (see figure 2.14), with the
dashed line representing the respective fractions collected. The gradient was
developed over 13.1 minutes with 0.1% TFA in water as solvent A and
acetonitrile with 10% A as solvent B with a flow rate of3 ml/min.
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Figure 2.18 Semi-preparative HPLC chromatogram of magainin 2 (>96 % purity) from
synthesis 3. The gradient was developed over 13.1 minutes with 0.1% TFA in
water as solvent A and acetonitrile with 10% A as solvent B with a flow rate of
3 mL/min.
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Figure 2.19 Positive mode ESI-MS of purified magainin 2 from synthesis 3.
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2.5 Conclusions
The main objectives of this chapter were to optimise and synthesise pure magainin 2 for
biological use.
In order to ensure a successful synthesis it is necessary for quality control checks on all
derivatives, even newly acquired ones, prior to synthesis. There are many reasons for the
degradation of derivatives, of which the most prevalent are storage conditions, for example:
temperature, moisture, light, volatile organic and inorganic contamination of reagents. During
our first synthesis, the aspartimide reaction on N22 was probably due to loss of side-chain
deprotection of S23, resulting in additional unwanted analogues and a decrease in peptide
yield. This highlights the importance of using high purity derivatives. The aspartimide
reaction can also be partially suppressed by the inclusion of 0.1 M HOBt in the deprotection
mixture [34]. In the second synthesis this problem was prevented by rigorously testing all
derivatives and activating agents, however attachment of the first C-terminal amino acid to
the resin linker is also particularly important. The extent of this first reaction will determine
the yield of final peptide, and sites on the resin not reacted in this initial process can
potentially become acylated in subsequent cycles, leading to the formation of related C-
terminally truncated by-products. Extreme care was taken during coupling of the first amino
acid for the second synthesis of magainin 2. The open hydroxyl groups on the resin, which
were most likely due to steric hindrance, were blocked using tBoc-Gly-OH. These safety
measures were effective in preventing the problems experienced in the first synthesis. We
were also cautious of incomplete couplings decreasing peptide yield and subsequently
overcompensated on amino acid excess concentrations. It worked in driving the reaction
cycles to completion over the first two-thirds of the peptide, but caused coupling and
deblocking problems over the last third. Coupling concentrations were decreased to the
recommended three-fold excess during a third synthesis, which prevented subsequent steric-
crowding and the formation of any truncated by-products, while still maintaining rigorous
testing on all the derivatives and activating agents. The oxidised magainin 2, although easily
separated, can be prevented in future syntheses by ensuring that the components of the reagent
K cleavage cocktail are of high quality.
These measures allowed us to finally synthesise magainin 2 of very high purity (>96%) for
use in biological experiments. In Chapter 3 I shall report on the optimisation of the AFM
technique and the visualisation of the effects of magainin 2 and melittin on target membranes.
Stellenbosch University http://scholar.sun.ac.za
2.32
2.6 References
1. Curtius T. (1881) J. Prakt. Chern. 24239
2. Fischer E. (1902) Ber. dtsch. Chern. Ges. 35 1095
3. Hofmeister F. (1902) Ergeb. Physiol. Bioi. Chern. Exp. Pharmacal. 1 759
4. Fischer E. (1906) Ber. dtsch. Chern. Ges. 39530
5. du Vigenaud V., Ressler C., Swann J.M., Roberts C.W., and Katsoyannis P.G. (1954)
J. Amer. Chern. Soc. 76 3115
6. Merrifield R. B. (1962) Fed. Proc. Fed. Amer. Soc. Exp. Bioi. 21412
7. Merrifield R. B. (1964) Biochemistry 3 1385
8. Kent S.B.H. (1988). Ann. Rev. Biochem. 57 957
9. Barany G., Kneib-Cordnier N. and Mullen D.G. (1987) Int. J. Peptide Protein Res.
1987705
10. Stewart J. M. and Young J.D. (1984) Solid phase peptide synthesis, 2nd edition, Pierce
Chern. Co. Rockford, Illinois, pp. 69-70
11. Atherton E., Fox H., Harkiss D., Logan C. J., Sheppard R. C. and Williams B. J.
(1978) J. Chern. Soc., Chern. Commun. 4 539
12. Jung G and Bayer E. (1988) Proc. 20th European Peptide Symposium, Walter de
Gruyter, Berlin, pp. 199-200
13. Fields G. B. and Noble R.L. (1990) Int. J. Peptide Protein Res. 35, 161
14. Grant, G. (1992) Synthetic peptides, W. H. Freeman & Co., New York
15. ZasloffM. (1987) Proc. Natl. Acad. Sci. USA 84 5449-5453
16. ZasloffM., Martin B., and Chen H.C. (1988) Proc. Nat!. Acad. Sci. USA 85910-913
17. Dathe M. and Wieprecht T. (1999) Biochim. Biophys. Acta 1462 71-87
18. Bechinger B. (1997) J. Membr. Bioi. 156 197-211
Stellenbosch University http://scholar.sun.ac.za
2.33
19. Ludtke S.J., He K., Heller W.T., Harroun T.A., Yang L. and Huang H.W. (1996)
Biochemistry 35 13723-13728
20. Steiner H., Hultmark D., Engstrom A., Bennich H. and Boman H.G. (1981) Nature
292246-248
21. Yang L., Harroun T.A., Weiss T.M., Ding L. and Huang H.W. (2001) Biophys. J. 81
1475-1485
22. Gait M.J. (1984) Oligonucleotide synthesis, In: Practical Approach Series (Eds.
Rickwood D. and Hames D.D.) IRL Press, Washington D.C., p.99
23. Rautenbach M. (1999) The synthesis and characterisation of analogues of the
antimicrobial peptide iturin A2, Ph.D. Thesis (Biochemistry), University of
Stellenbosch, pp.28-31
24. Atherton E. and Sheppard R.C. (1989) Solid phase synthesis: A practical approach, In:
The practical approach series (Series Eds., Rickwood D., and Hames B.D.), IRL Press,
Oxford University Press, Oxford, pp.I-61
25. Gloor A.P., Hoare S.M., Lawless K., Steinauer RA., White P., Young C.W.
(1994/1995) Novabiochem 94/95 Catalogue and Peptide Synthesis handbook, ppSl-
S42
26. Bodasky M. (1984) Principles of peptide synthesis (Eds. Hafner K., Rees C.W., Trost
B.M., Lehn J., Von Ragne Schleyer P., Zahradnik R), Sringer Verlag, Berlin, pp. 9-52
27. Hoeg-Jensen T., Jakobsen M.H., Olsen CD. and Holm A. (1991) Tetrahedron Lett. 32
7617-7620
28. Kaiser E., Colescott RL., Bossinger C.D. and Cook P.I. (1970) Anal. Biochem. 34
595-598
29. Carpino L.A. and Han G.Y. (1972) J.Org. Chern. 37 3404-3406
30. Lourens G.D. (1999) The influence of immobilisation and peptide structure on the
bioactivity of model antimicrobial peptides, M.Sc. Thesis (Biochemistry), University
of Stell enbosch, pp. 2.11-2.12
Stellenbosch University http://scholar.sun.ac.za
2.34
31. Du Toit E.A. (1999) The development of an antimicrobial assay and its use in the
investigation of the combined effect of tetracycline and synthetic antimicrobial
peptides on strains of Escherichia coli, M.Sc. Thesis (Biochemistry), University of
Stellenbosch, pp. 2.12-2.13
32. Rautenbach M. (1989) The synthesis and characterisation of antigenic peptide
determinants, M.Sc. Thesis (Biochemistry), University of Pretoria, pp.lI-25, 28-33,
80-82
33. King D.S., Fields e.G. and Fields G.B. (1990) Int. J. Peptide Protein Res. 36 255-266
34. Lauer J.L., Fields e.G. and Fields G.B. (1994) Lett. Pept. Sci., 1197
Stellenbosch University http://scholar.sun.ac.za
3.1
Chapter 3
Imaging the action of membrane-active peptides on
different target cells using Atomic Force Microscopy
3.1 Introduction
Over a decade ago, it was realised that antimicrobial peptides played a crucial role in nature
as a means of "front-line" defence against invading organisms [1,2]. With the increasing
problem of pathogenic organisms that are resistant to conventional antibiotics, there is
growing interest in the application of antimicrobial peptides to treat infection. Research is
currently focused on understanding the mechanism of action of these antimicrobial peptides
to improve their potency and specificity, which will allow the development of the next
generation of antibiotic [1].
This aim is complicated by the structural diversity found among antimicrobial peptides, and
the different mechanisms of action they utilise [3-7]. For example, two well-known
membrane-active peptides, melittin and magainin, differ widely in their target specificity
and proposed mechanisms of action. Magainin, a 23-residue antimicrobial peptide, was
discovered from the granular gland of the skin of the African clawed frog Xenopus laevis
[8], and exhibits a broad spectrum of activity against bacteria, fungi, and protozoa typically
in the concentration range of 10-100 ug/ml, [9-13]. In contrast, more than 1 mg/mL of
magainin is required to lyse erythrocytes [14], indicating selective toxicity against micro-
organisms. Melittin, a bee venom 26-residue peptide amide, does not share the selective
bioactivity properties of magainin. It is extremely haemolytic and shows minimal
selectivity towards a broad range of microbial target cells [15].
Studies using model membrane systems have been used to better understand the influence
of an antimicrobial peptide's structure on its toxicity and mechanism of action. The most
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substantiated models (see Section 1.1.3) for toxic peptides (i.e. melittin) and non-toxic
peptides (i.e. magainin) include the "barrel-stave" [16], "carpet" [17] and
"wormhole/toroidal" pore models [18]. These studies also prompted the realisation that the
mechanism of action was not only influenced by the structural properties of the peptide, but
also by the variation in lipid composition and structure found among different target cell
membranes. Biological membranes are predominantly arranged in a bilayer with the polar
head groups facing outwards and the non-polar acyl chain tails pointing inward, however
alternative non-lamellar phases also exist. This is because the structural properties of some
lipids can be positive or negative-curvature inducing [19]. Lipids with small head groups
promote negative curvature strain (see Section 1.1.2), which can form inverted phases if the
bilayer stress reaches a critical point [19]. Alternatively, large head groups promote positive
curvature strain (see Section 1.1.2), which can form micelles, if the bilayer stress reaches a
critical point [19].
So if we analyse human and goat erythrocyte membranes (see Table 3.1), which can be
considered representative of mammalian cell membranes, we find that the outer leaflet of
the membrane consists mainly of the choline phosphatides, phosphatidylcholine (PC) and
sphingomyelin (SM) [20,21]. The inner leaflet of the membrane is mainly composed of the
aminophosphatides, phosphatidylethanolamine (PE) and phosphatidylserine (PS) [20,21].
In contrast, E. coli (Table 3.1) shows an outer membrane consisting mainly of
lipopolysacharides [22-24], while the inner membrane is mainly composed of cardiolipin
(CL), phosphatidylglycerol (pG) and PE [25,26]. The specific properties of these structural
components will influence erythrocyte and E. coli cell membranes towards positive or
negative curvature strain.
Peptides can also influence the tendency of lipids to form non-lamellar phases [19] by
inducing positive or negative curvature strain. Peptides that promote positive curvature
strain on membranes can be associated with the formation of pores or lesions, depending on
the orientation of the peptide [27]. In contrast, peptides that promote negative curvature
strain can be associated with membrane collapse [27].
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Table 3.1 Lipid composition in human and goat erythrocytes and in E. coli [21,22].
Phospholipid % in erythrocyte % inE. coli
plasma cell membrane
membranes (inner
Human; Goat membrane)
CL 0; 0 12
PG 0; 0 6
PE 28.4; 27.8 82
PS 13.4; 20.8 0
PC 31; 0 0
SM 23.5; 45.9 0
Other 3.7; 5.5 0
Clearly, the combined influence of diverse peptide structure and target membrane
complicates our understanding of the mechanism of action. However, the availability of
efficient analytical and preparative techniques [see reviews 28-31] has allowed the
application of many biophysical methods to determine the orientation, conformation, and
interaction of peptides with model membranes. Through these model membrane studies,
various membrane permeation models have been proposed for different peptide classes
[29]. However, some peptides have also shown bactericidal activity via alternative
mechanisms other than membrane permeation. For example, Park et al [32] compared the
mechanism of action of buforin II with magainin 2. It was shown that unlike magainin 2,
buforin II killed E. coli without lysing the cell membrane, even though both are structurally
similar linear amphipathic a-helical peptides (for more examples see Section 1.1.3.5-
1.1.3.9). This example highlights the fact that there are still many uncertainties surrounding
our understanding of the mechanism of action of even this well-studied group of peptides.
One reason for this is that although model membrane studies provide a wealth of
information, they do not mimic the complexity of natural cell membranes. Model
membrane studies cannot determine the combined curvature properties of all the
phospholipid and protein components of a cell membrane, nor decipher the influence of
peptide structure on the mechanism of action of a target cell membrane.
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An alternative is to combine data obtained from model membrane studies with defined
target cell studies. For example, the latest advances in microscopy allow us to visualise the
effects of antimicrobial peptides on target cell membranes in the nanometer range. A
number of microscopy techniques are available with resolution ranging from micrometers
in the case of light microscopy, through to the sub-nanometer range for electron
microscopy. In most of these methods the samples need to be coloured or fixed. In the case
of cell membranes, treatment could result in conformational changes of the peptides and
membrane surfaces. This limits the applications and conclusions concerning the mechanism
of action of antimicrobial peptides. However, the last decade has seen rapid development in
the field of scanning probe microscopy [33], more specifically atomic force microscopy,
which has opened new and exciting applications in the natural sciences.
In the May 2000 edition of Nature Structural Biology [34], Feng briefly described the
applications of atomic force microscopy (AFM) and how samples can be imaged (to
nanometer resolution, without fixing) in air or under water. In AFM, the sample is scanned
with a cantilever and the deflections are recorded by a computer, which generates a 3D
image of the sample's surface [35]. This technique can provide us with new insights into
understanding the mechanism of action of antimicrobial peptides.
We developed a method for using AFM to image the morphological changes induced by the
linear a-helical peptides, melittin 1 and magainin 21, on target membranes without using
fixing agents. Increasing peptide dose-responses were compared to the AFM images of the
target-membranes obtained. From these images we were able to correlate our results with
current membrane-permeation models and furthermore conclude that lipid composition
plays a fundamental role in the mechanism of action and selectivity of antimicrobial
peptides.
1 Melittin and magainin were chosen for this study because of their contrasting selective properties. The
structural details for these two peptides are highlighted in Section 2.1.
Stellenbosch University http://scholar.sun.ac.za
3.5
3.2 Materials
Escherichia coli (HB 101) and erythrocytes isolated from freshly drawn goat blood were
used as peptide target cells in all experiments. Melittin was from Sigma-Aldrich Chemie
(Steinheim, Germany). Magainin 2 was synthesised at room temperature (20-25°C)
according to the Fmoc-polyamide protocol [36] (see Chapter 2). Analytical quality water
was prepared by filtering glass-distilled water through aMillipore Milli Q® water
purification system. Glucose was purchased from BDH Chemicals (Poole, England), and
trisodium citrate was from B&M Scientific cc. (Cape Town, South Africa). Sodium
chloride and glacial acetic acid were from Saarchem (Krugersdorp, South Africa). Citric
acid, disodium hydrogen phosphate, and formaldehyde (99%) were from Merck
(Darmstadt, Germany). Potassium dihydrogen phosphate, tryptone soy agar (constituents in
gIL: 15.0 tryptone, 5.0 soy peptone, 5.0 sodium chloride, 13.0 agar, pH 7.3, +-0.1) and
tryptone soy broth (constituents in gIL: 17.0 tryptone, 3.0 soy peptone, 5.0 sodium chloride,
2.5 dipotassium hydrogen phosphate, 2.5 dextrose, pH 7.3, +-0.1) were from Merck
(Midrand, South Africa). Potassium chloride was purchased from Trinity Scientific
(Hillcrest, South Africa). Microtiter plates (Nunc-Imuno™ Maxisorp) were from Nalge
NUNC International (Roskilde, Denmark), Falcon® tubes from Becton Dickinson Labware
(Lincoln Park, USA), and culture dishes from Quality Scientific Plastics (USA).
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3.3 Methods
3.3.1 Preparation of erythrocytes
The haemolytic activity of melittin and magainin 2 was investigated using goat red blood
cells'. Blood was drawn and stored with equal amounts of Alsevers solution (2.05%
glucose, 0.80% sodium citrate, 0.42% sodium chloride and 0.055% citric acid, miv, pH 7.2)
at 4°C for 5 days [37]. To ensure erythrocyte separation and stabilisation, the blood
samples were decanted and washed with fresh Alsevers solution every 24 hours.
Erythrocytes were separated directly before use by centrifugation (900g for 10 minutes)
washed and diluted (2.5% erythrocyte solution) in PBS (8% NaCl, 0.2% KCI, 1.15%
Na2HP04 and 0.2% KH2P04, miv, pH 7.2) [37].
3.3.2 Haemolysis dose response assays
The prepared erythrocytes were incubated at room temperature (22±2°C) for 30 minutes
using an optimised concentration range of melittin (doubling dilutions, 0.2nM-3.51f..lM)and
magainin 2 (doubling dilutions, 0.39-202f..lM) diluted in PBS (0.15 M, pH 7.2). To
determine the extent of haemolysis, the cells and cell debris were removed by
centrifugation for five minutes on a small bench-top centrifuge (picofuge®) and the
absorbance of the supernatants measured at 405 nm using a Multiscan Titertek microtitre
plate reader. The minimum haemolytic concentration (MHC or HCso) was defined as the
peptide concentration leading to 50% haemolysis'. Zero haemolysis (blank) and 100%
2 This project was initiated at a time when the newly built BIOPEP and AFM laboratories did not have the
necessary human blood hazard protocols in place, therefore non-human blood was used instead. We chose
goat blood over rabbit blood, because we were insured of a constant supply of samples from animals
uncontaminated by any physiological treatments, which could change erythrocyte morphology or function.
3 Deduced from the following equation: Y= lOO/(1+10(logHCsoI Hillslope)where:
log HCso=X-value of response halfway between top and bottom; Hill Slope = Hill Coefficient
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haemolysis were determined by measuring the absorbance of the supernatant of the
erythrocytes suspended in PBS (0.15 M, pH 7.2) and melittin (1 mg/mL) respectively.
3.3.3 Preparation of erythrocytes for AFM
The erythrocytes" were incubated at ambient temperature with the peptide solutions for
three minutes at different concentrations, as determined from the dose response assays
(Fig. 3.1). Formaldehyde control samples were incubated for an additional three minutes
with a 2% formaldehyde solution, and all samples were washed twice'' in PBS (0.15 M, pH
7.2). 5 p l of each sample was added onto a freshly cleaved mica surface. The residual
solution was removed with a piece of filter paper and allowed to air-dry for approximately
three minutes before imaging. Each sample was imaged for approximately 10 minutes.
Drying-related changes to the erythrocyte surface morphology became evident after 20
minutes.
3.3.4 Preparation of bacterial cells
The anti-bacterial activity of melittin and magainin 2 was tested using E. coli (HBIOI).
Bacterial cells were incubated at 37°C for 24 hours on a tryptone agar plate. Five colonies
were selected and transferred to 6 mL tryptone soy broth (TSB) and grown overnight at
37°C. 200 ul, of the suspension was sub-cultured in 7 mL TSB and grown to an optical
density (OD) ofO.6 at 620nm and further diluted to an OD ofO.285 [38].
4 The erythrocyte concentration used during the haemolysis assay was optimised to ensure that no bunching
occurred on the mica surface during imaging. This became evident during our initial image optimisation test
runs (before conducting the haemolysis assays), where extreme bunching and double cell layers made for
ineffective data analysis. We found that a 2.5% erythrocyte solution provided an effective spread of cells over
a 511m2imaging area.
5 Alsevers solution affected our initial data analysis. Therefore the washing step was introduced during
erythrocyte preparation and again used during image preparation to also clear away cell debris. This step did
not affect the peptide image data generated.
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3.3.5 Antibacterial activity dose response assays
The dose-responses of melittin (doubling dilutions, 0.43-17.57 u.M) and magainin 2
(doubling dilutions, 0.57-36.83 u.M) were determined by incubating 70 ul. of the bacterial
suspension and 30 ul. of each peptide (dissolved in analytical quality water) on a microtitre
plate. To determine the extent of growth inhibition, light dispersion was measured after 17
hours of incubation (37°C) at 620nm using a Multiscan Titertek microtitre plate reader".
100% growth was determined using 70j.l1bacterial suspension and 30j.l1H20 (analytical
quality). 100% inhibition was determined using 1mg/ml melittin.
3.3.6 Preparation of E. colifor AFM
To prepare the bacterial samples for imaging, 70 ul of the sub-cultured bacterial suspension
was incubated for three minutes with 30 ul of each peptide. Melittin and magainin 2
samples were dissolved in analytical quality water using effective concentrations
determined from the dose response assays (see 3.4.1.2). The E. coli samples were
centrifuged at lOOOg(Eppendorf Centrifuge 5417C) for ten minutes and the supernatant
discarded. The pellet was then gently resuspended in a 1mL NaCI solution (0.9 % mJv, pH
7.2) and 5 ul. added onto a freshly cleaved mica surface. The residual solution was
removed with a piece of filter paper and allowed to air-dry for approximately three minutes
before imaging. Each sample was imaged for approximately 10 minutes. Drying-related
changes to the E. coli surface morphology became evident after 20 minutes.
6 The equation used for the sigmoidal curve with variable slope was:
y= bottom + (top-bottom)/(1+1010gIC!OXHill slope ) where the bottom is the Y-value at the bottom plateau and
top is the Y-value at the top of the plateau; IC50 is the X-value of the response halfway between top and
bottom; Hill slope = Hill coeffecient. IC 50 is 50% inhibitory concentration.
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3.3.7 AFM Imaging
The TMX 2000 Explorer (Topometrix, Santa Barbara, CA) atomic force microscope was
used for all imaging of erythrocytes and bacterial cells. The imaging parameters were
optimised by varying the resonance frequency, force constant and set point until clear
images were obtained without damaging the samples. We operated in contact mode using
commercially available v-shaped cantilevers (200x18f!m) from Topometrix, with a
resonance frequency of 5-15kHz and a force constant of 0.032N/m. SbN4 pyrimidal light
force tips were used and imaging forces were adjusted to a set point of -30nA. A 165nm
step height standard Topometrix grid was used for calibration of the height (z) and lateral
(x,y) measurements of the stage. Data analysis was performed using Topometrix SPM Lab
version 3.06.06.
3.4 Results
3.4.1 Dose response parameters
3.4.1.1 Erythrocyte dose-response
Melittin and magainin 2 showed a MHC (minimum haemolytic concentration) of 0.36 uM
and 64 u.M (Fig. 3.1), and a Hill slope factor of 0.97 and 6.144 respectively. Peptide
concentrations above and below the MHC were used during AFM imaging to record the
structural changes induced by melittin and magainin 2 on erythrocytes.
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Figure 3.1 A graph illustrating melittin and magainin 2 dose-response parameters for
erythrocytes.
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Figure 3.2 A graph illustrating melittin and magainin 2 dose-response parameters for
E. coli.
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3.4.1.2 E. coli dose-response
In contrast to the erythrocyte dose-response parameters, melittin and magainin 2 showed a
similar MIC (minimum inhibitory concentration) of 6.3 IlM and l4.96IlM, and a Hill slope
factor of -17 and -l3 respectively (Fig 3.2). During AFM imaging, peptide concentrations
above and below the MIC were used to record the structural changes induced by melittin
and magainin 2 on E. coli.
3.4.2 Atomic Force Microscopy
During the AFM studies we imaged over 100 blank controls at 51lm2 to capture all possible
morphological variations on the target cells for comparison with the peptide data to ensure
that the morphological changes were indeed induced by and unique to the peptide. Image
collection on melittin and magainin 2 was also continued until representative data regarding
all morphological cell variations had been captured.
3.4.2.1 Erythrocyte cell shape
Our major concern during the visualisation process was the influence our sample
preparation would have on the images obtained, as it did not involve any form of fixation.
Instead visualisation took place at ambient temperature and atmosphere, with slight drying
of the samples as a result of the removal of residual water. It was noticed that the cells
flattened out on the mica surface, most likely as a result of the combined effect of semi-
drying and hydrophobic association with the mica. This change in cell shape did not
influence the initial membrane interaction of melittin and magainin 2 because of two
reasons: First, the interaction between the peptides and the erythrocytes took place under
physiological conditions before the removal of any residual water. Second, the specific
properties of the membrane skeleton impart the strength and deformability required for the
cell to withstand the tremendous forces of circulation and to squeeze through
microcapillaries [39]. This allows flattening or swelling of the cells to occur without
initially compromising the membrane structure of the erythrocytes. This also allows semi-
drying to occur without influencing the surface-structure changes imaged after peptide
interaction «20 min).
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The average diameter of goat erythrocytes reported in literature is 2.4 - 3 11m[40]. Our wet
images (no drying), displayed a typical doughnut shape (Fig. 3.3a) with a mean average
diameter of 3.1O±0.03 11m. The discoidal erythrocyte shape corresponds to the minimum of
its membrane elastic energy [41]. This consists of the bilayer-bending energies and the
skeleton shear elastic energy, while the cell volume and the membrane area are kept
constant [41]. Although it was possible to generate wet images, we could not produce
consistent results due to interference with the cantilever, therefore semi-drying of the
samples was necessary to limit this interference. The semi-dry erythrocyte controls
(Fig. 3.3b) although slightly flattened, still retained the characteristic indentation and
membrane morphology of the wet images with a mean average diameter of 3.70±0.07 11m
(see Table 3.2). The addition of formaldehyde prevented cell flattening (Fig. 3.3c), but
resulted in an increase in diameter to a mean average of 4.70±O.l9Ilm. This occurs because
formaldehyde induces changes in protein conformation, which in turn would effect peptide-
lipid interactions [42]. Subsequently, this fixing agent was only used as a control.
The incubation with melittin (Fig. 3.4a) and magainin 2 (Fig. 3.4b) below their MHC
caused the cells to swell to form a convex shape. The melittin and magainin 2 treated
erythrocytes increased from a mean average diameter of 3.70±0.07 11mto 4.65±0.12 11m
and 4.70±0.21 11mrespectively (Table 3.2). The formaldehyde samples pre-treated with
peptides showed no further increase in size. This resuIt was as expected, because cross-
linking of membrane proteins and phospholipid-headgroups limits the elasticity of the
membrane and the swelling that occurs before lysis.
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Table 3.2 Size parameters for semi-dry erythrocytes and E. coli.
Target cell Blanks Melittin Magainin 2
Erythrocytes 3.70±0.07Ilm 4.65±O.l2Ilm 4.70±0.2lllm(n=50) (n=40) (n=40)
Erythrocytes and 4.70±O.l8Ilm 4.97±0.2lllm 4.61±0.17Ilm
formaldehyde (n=lO) (n=lO) (n=lO)
3.4.2.2 Erythrocyte surface morphology
Fine structural details of the erythrocyte lipid bilayer, such as proteins protruding from the
lipid surface, were not visible. The addition of the peptides caused the formation of lesions,
grooves or vesicles, depending on the peptide and concentration used.
The addition of melittin at 0.2l81lM (below MHC) resulted in the formation of distinct
lesions on the surface of the erythrocytes (Fig. 3.5a). These lesions varied in size from 70-
95nm in surface diameter, however the cell structure still remained intact. It must be
emphasised that this is 10-fold larger than "pores" found in literature [64], indicating that
we are observing an event consequent to melittin's mechanism of action. This is due to the
resolution constraints of our atomic force microscope methodology? The largest lesions
generally appeared in the central region of the cell (biconcave area) connected by lines of
smaller lesions clustered together. It is possible that the change in surface infrastructure and
membrane tension make the central area more vulnerable to peptide attack. The close
grouping or banding of lesions may be the consequence of lipid segregation causing same-
type lipids to cluster together [19]. This in tum would cause lesions to occur around those
lipid types, which are structurally more vulnerable to attack (detailed in discussion). Higher
melittin concentrations (OAIlM, 10% higher than MHC) resulted in additional lesions, cell
fusion and vesiculation (Fig. 3.5b).
7 This hold true for all images of erythrocytes and E. coli, in this AFM study.
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A closer analysis of melittin samples below the MHC at 0.218 uM, show that the lesions
are connected by lines or grooves (Fig. 3.6), in fact, these "lines/grooves" appear to
periodically widen to form the lesions observed (70-95nm).
In contrast to the lesions observed in melittin-treated erythrocytes, the addition of magainin
2 (50.7flM, below MHC) resulted in the formation of distinct grooves (consequent to
magainins mechanism of action) on the surface of the taught cell (Fig. 3.7a) with possible
vesiculation damage (Fig. 3.7b). Higher concentrations (101flM, >50% higher than MHC)
resulted in irreversible haemolysis caused by cell surface collapse (Fig 3.7c). This resulted
in more cell debris and minimal vesicle formation when compared to the structural changes
induced by the melittin samples. Furthermore we observed that although the magainin 2
samples showed similar "lines/grooves" to melittin, they did not appear to widen to form
large visible lesions (Fig. 3.8), although there was one rare exception where a small lesion
(95nm in diameter) was visible (Fig. 3.9). The results correlated well with the dose
response parameters, allowing us to assign specific mechanisms of action for melittin and
magainin 2 based on previous model membrane studies (detailed in discussion).
Stellenbosch University http://scholar.sun.ac.za
AB
C
Figure 3.3
3.15
t333.S2 nm
4.02 urn
[
-21.3 nA
-32.08 nA
4.49!Jm
f-22.14 nA
5.01 prn
AFM images of erythrocyte controls A: wet image; B: semi-dry image;
C: formaldehyde control image.
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Figure 3.4 A: AFM image of melittin-induced erythrocyte swelling below MHC (0.218f.lM)
and B: AFM image of magainin-induced erythrocyte swelling below MHC (50.7f.lM) with
arrow indicating grooves forming on surface.
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Figure 3.5 A: Melittin-induced lesion (circle) below MHC (O.218f.!M) and B:
melittin-induced lesions above MHC (OAOf.!M),with forming vesicles
(circles).
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Figure 3.6 AFM images on the erythrocyte surface with circles indicating the variation
in shape and size that occurs as a result of melittin-induced lesions (70-
95nm) below MHC (0.218~M).
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Figure 3.7 A: Magainin-induced groove (circle) and B: magainin-induced cytoplasm
leakage on erythrocyte surface below the MHC (50.7j.lM). C: Magainin-
induced haemolysis (cell outline indicated by circle), above MHC
(lOlj.lM).
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Figure 3.8 AFM images with circles indicating magainin-induced grooves below MHC
(50.7I-!M) on the erythrocyte surface.
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Figure 3.9 Comparison of AFM images indicating lesions (circles) on erythrocytes
induced by A: melittin and B: magainin 2. It is interesting to note that the
melittin sample appear to form grooves which widen into small lesions.
Although a similar event occured with the magainin 2 sample it should be
mentioned that this lesion (95nm) was the only one captured for magainin 2.
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3.4.2.3 Bacterial cell shape and morphology
The rigid cell wall of E. coli supports the cell structure during imaging, preventing the
distortion observed with the erythrocyte cells. Figure 3.10 represents the typical structure
recorded for E. coli with an average length of 3.32±0.14 urn and width of 1.91±0.14
(n=25). This is in accordance with cell sizes reported in literature [43]. We did not observe
the distinctive swelling found for the erythrocytes due to the structural stability provided by
the bacterial cell wall.
Below melittin's MIC (2.17 !!M), structural changes of the bacterial cell wall were
induced, resulting in the formation of lesions (consequent to melittin's mechanism of
action) and an outward bulging of the inner membrane (Fig. 3.11, top image). A further
increase in concentration (8.78 !!M, ±40% times higher than the MIC) resulted in lysis of
the cell (Fig. 3.11, bottom image), with minimal vesiculation.
Below the MIC, at a concentration of 1.08!!M, melittin appeared to form similar lesions
(95-130nm) with connecting lines on E. coli (Fig. 3.12) as observed for the erythrocytes
(70-95nm; Fig. 3.6). At a higher concentration of 2.18!!M, still below the MIC, the lesions
appeared to decrease in size (30-85nm) and appeared more randomly distributed, with only
some minimal vesiculation (Fig. 3.13).
Below magainin's MIC (4.1!!M), we also observed lesions (consequent to magainin's
mechanism of action) on the surface and an outward bulging of the inner membrane of E.
coli (Fig. 3.14a). At approximately twice the concentration of melittin, magainin 2
(20.3!!M, ±35% higher than MIC) still showed lesions and the same outward leakage of the
inner membrane as below the MIC, but also induced mass vesiculation (Fig. 3.14b), which
was not observed for melittin-treated samples (Fig. 3.11, bottom).Electron microscopy
studies have also shown magainin-induced lesions or blebs on the bacterial membrane [13].
Below the MIC, at a concentration of2.02!!M, the magainin 2 lesions (150-340nm; Fig.
3.15) with connecting lines appeared larger than the melittin lesions (95-130nm; Fig. 3.12).
At a higher concentration of 4.06 !!M, still below the MIC, the magainin 2 lesions appeared
to be of similar size to the lower concentration level (200-360nm; Fig. 3.16).
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Figure 3.10 AFM control image of E.coli.
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Figure 3.11 AFM images of E. coli with melittin-induced lesions (top image) below the MIC
(2.l7~M) resulting in an outward bulging of the inner membrane (circle). Melittin-
induced lysis (bottom image) above the MIC (8.78~M).
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Figure 3.12 AFM images with circles indicating melittin-induced lesions (95-130nm)
below MIe (l.081!M) on the E. coli surface.
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Figure 3.13 AFM images on the E. coli surface with circles indicating smaller melittin-
induced lesions (30-85nm) at higher concentration, but still below MIC
(2.l8f..lM).
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Figure 3.14 AFM images of E. coli with A: magainin-induced lesions resulting in an
outward-bulging of the cells membrane below the MIC (4.1J.lM) and B: mass
vesiculation above the MIC (20.3J.lM).
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Figure 3.15 AFM images with circles indicating large magainin-induced lesions (150-
340nm) below MIC (2.021lM) on the E. coli surface.
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Figure 3.16 AFM images with circles indicating large magainin-induced lesions (200-
360nm) still below MIC (4.06J.lM)on the E. coli surface.
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3.5 Discussion
Peptide orientation in a target membrane has developed a firm foothold in the literature as a
strong indicator of mechanism of action [64]. Horizontal orientation is indicative of
membrane perturbation by means of the "carpeting" model, whereas perpendicular
orientation points towards a pore-like mechanism, such as the "barrel-stave" model [64]. A
change in orientation from parallel to perpendicular is indicative of pore-formation by
means of the ''toroidal'' model [64].
Magainin's steep dose-response gradient on erthrocytes (Fig. 3.1) appears similar to an
on/off switch suggesting a mechanism of action similar to the "carpeting" model. This is a
situation in which lytic peptides are in contact with the phospholipid head group throughout
the entire process of membrane permeation [47,48]. According to this model, lytic peptides
bind with a horizontal orientation onto the surface of the target membrane and cover it in a
carpet-like manner. Compared to the controls (Fig 3.3b), we observed that magainin 2
induces swelling (Fig. 3.4b) and forms grooves below the MHC that in some samples span
the erythrocyte membrane (Fig. 3.7a, Fig. 3.8) resulting in haemoglobin leakage (Fig. 3.7b).
Above the MHC, we observed magainin-induced membrane collapse (Fig. 3.7c). Previous
studies supporting the carpet mechanism indicate that magainin's weaker hydrophobic
interaction with the erythrocyte membrane results in the formation of a less-structured u-
helix [49-51]. Consequently, magainin 2 orientates itself parallel to the membrane
[50,52,53] allowing shallow penetration of its hydrophobic residues into the hydrophobic
core [52,54]. The shallow penetration prevents the induction of positive curvature on the
PC and SM components of the erythrocyte membrane, and the natural predominant effect
of negative curvature strain remains, preventing the formation of pores [27]. If this is the
case, then mass accumulation and shallow penetration of magainin 2 on the erythrocyte
surface will cause the membrane to fold inwards forming shallow grooves as seen in Figure
3.7a. However, this does not explain why the grooves appear to form star or ladder like
patterns (Fig. 3.8). Previous studies have indicated that biological membranes have specific
lateral organisation and that lipid segregation occurs and has physiological relevance
[19,46]. If same-type lipids were grouped together in bands it would make certain areas of
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the target membrane more vulnerable to peptide attack, depending on the prominent
curvature strain of that lipid-type. This could explain why magainin-induced grooves on
erythrocyte membranes did not appear to be randomly distributed. Instead, they were
always connected by lines or clustered in bands across the membrane (Fig. 3.8). Above the
MHC, the grooves or lines would continue to expand due to the accumulation of peptide.
This progressive destabilisation of the membrane surface eventually leads to membrane
collapse, as seen in Figure 3.7c.
Our observations indicate that magainin 2 maintains a parallel orientation on erythrocyte
membranes, which in tum supports a mechanism similar to the "carpeting" model, below
and above the MHC [47,48].
In contrast, the "barrel-stave" mechanism [16] has featured strongly in the literature over
the last few years as a possible mechanism of action for melittin [64], but is this really the
case? This mechanism describes the formation of transmembrane channels/pores through
vertical bundles of amphipathic a-helices. These bundles are arranged so that their
hydrophobic surfaces insert into and interact with the lipid core of the membrane, while
their hydrophilic surfaces face each other to form the interior wall of the aqueous pore,
which is exposed to the hydrophilic exterior environment. This model fits into previous
studies that have shown that melittin orientates itself perpendicular to the membrane normal
[44,45], and can induce positive curvature strain [46] on PC and SM bilayers by deep
insertion into the bilayer causing swelling of the cell to occur. However, recent contrasting
studies indicate variations in melittin orientation and pore size making the ''toroidal'' model
a more likely candidate [64]. The model describes changes in peptide orientation during
insertion, from horizontal to vertical, while maintaining contact with the lipid head group.
Consequently the lipid monolayer bends inwards with the peptide, from the top leaflet to
the bottom leaflet, so that unlike the "barrel-stave" model, both the lipid head groups and
the peptides line the pore. The gradual increase of the dose-response curve gradient for
melittin (Fig. 3.1) supports the "toroidal" model. Compared to the controls (Fig 3.3b), we
observed that there is swelling of the cell below the MHC (Fig. 3.4a) and lesions connected
by grooves (Fig 3.5a, Fig. 3.6). Above the MHC more lesions form, which eventually
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causes segments of the membrane to break away as smaller vesicles (Fig. 3.5b), ultimately
resulting in the destruction of the erythrocyte.
If melittin undergoes an orientation change [64] it can be expected that a certain
proportional part of bulk phase will be in a horizontal orientation and a certain proportion
in a perpendicular orientation. The portion of melittin in the horizontal orientation will form
grooves, based on the same argument presented for magainin 2 (shallow penetration
prevents positive curvature of the erythrocyte membrane). The portion of melittin in the
perpendicular orientation will undergo deep penetration and induce positive curvature on
the erythrocyte membrane. Previous studies on melittin have shown that positive curvature
strain can be associated with the formation of pores [46] and that the progressive
recruitment of additional melittin monomers will induce excessive positive curvature strain
on the membrane [46]. This would increase pore formation, swelling and membrane stress,
ultimately rupturing the entire surface of the cell. This would explain the lesions we
observed (Fig 3.5a, Fig. 3.6). As a greater proportion of the melittin bulk phase undergoes
transition to a perpendicular orientation, it can be expected that the melittin-rich grooves
will periodically widen to form more lesions (Fig. 3.6).
Our observations support the re-orientation of melittin on the erythrocyte surface, which in
tum supports the "toroidal" model as a mechanism of melittin-induced pore formation on
erythrocytes. Furthermore, the small lesion formed by magainin 2 shows (Fig. 3.9), but
does not equivocally prove, that on rare occasions it can also change orientation from
parallel to perpendicular (see Chapter 4: "Phase-Transition" model). Although studies
indicate that magainin 2 has a parallel orientation [50,52,53], it must be taken into account
that most studies make use of bulk phase averages, opening the possibility that a small
percentage of magainin 2 could have an alternative orientation.
The interaction of peptides with E. coli (Fig. 3.10) differs from erythrocytes due to the
presence of an outer cell wall containing lipopolysaccharides (LPS) and differences in inner
membrane phospholipid composition (Table 3.1). The electronegative environment of the
cell wall also increases the binding affinity of melittin and magainin 2. Studies have shown
that magainin 2 does bind to the LPS, permeabilising the outer membrane [59], and that
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some peptides translocate to the inner membrane and disrupt the infrastructure [23,24]. Our
images confirm these studies as cell wall disruption and inner membrane bulging of
magainin-treated E. coli was observed below the MIC (Fig. 3.14a). Furthermore, magainin-
induced lesions on the inner membrane, below the MIC, at 2.021lM (Fig. 3.15; 150-340nm)
and 4.061lM (Fig. 3.16; 200-360nm) were of similar diameter, but larger than those induced
by melittin (Fig. 3.12), albeit at twice the concentration. At higher concentrations above the
MIC, magainin-induced vesiculation occurred (Fig. 3.14b), similar to that observed for
melittin on erythrocytes (Fig. 3.5b), which as previously indicated also appears to undergo
membrane re-orientation.
Previous model membrane studies indicate that magainin 2 initially interacts in a parallel
orientation and imposes positive curvature strain on PE model membranes [46,60], even
though PE is naturally negative-curvature inducing. This results in membrane thinning
which increases the membrane deformation energy, thereby destabilising the surface-lying
state inducing a transmembrane orientation [61] and pore formation with the helices of
magainin 2 intercalated between the lipid head groups [18]. The progressive recruitment of
additional magainin 2 monomers will increase pore formation, swelling and membrane
stress, ultimately rupturing the surface of the cell to form the grooves and lesions observed
in Figure 3.15 and 3.16.
Our observations indicate that magainin 2 undergoes a similar re-orientation on the E. coli
membrane surface as observed with melittin on erythrocyte membranes. Furthermore, this
supports studies on magainin's mechanism [27] in which investigators proposed a "toroidal
pore" mechanism of action on the inner membrane of E. coli.
Melittin induced the formation of lesions similar to magainin 2 on the surface of the E. coli
cell wall, below the MIC, followed by an outward bulging of the inner membrane
(Fig. 3.11, top image). The outward bulging is most likely facilitated by the translocation
and binding of melittin to the inner membrane which disrupts the supporting infrastructure
network. As the inner membrane bulges outwards additional melittin will also bind,
increasing the rate of lysis. Furthermore, melittin-induced lesions on the inner membrane
below the MIC, at a concentration of 1.08 IlM (Figs. 3.12; 95-130nm), were of similar
diameter to the melittin-induced lesions on erythrocyte membranes (Fig. 3.6; 70-95nm),
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which as previously indicated also appears to undergo membrane re-orientation. At a higher
concentration of 4.06IlM, still below the MIe (Fig. 3.13; 30-85nm), the lesions appeared
smaller. At higher concentrations above the MIe, cell lysis occurred, however unlike
magainin 2 very little vesiculation was evident (Fig. 3.11, bottom image).
Studies have shown that melittin induces positive curvature strain on PE and PG vesicles
[55,56,57], which are the major components of the inner membrane (Table 3.1).
Furthermore, the induction of positive curvature strain is associated with the formation of
pores [27]. Melittin-induced lesions above the MIe (Figs. 3.12; 95-130nm; 1.08IlM), could
therefore be the result of pore-formation [58], which is supported by the induction of
positive curvature by melittin, again, as on erythrocyte membranes, indicating a re-
orientation on the membrane surface and supporting a "toroidal" mechanism of action.
However, the decrease in lesion size below the MIe (Fig. 3.13; 30-85nm; 4.061lM) and
decrease in vesiculation (Fig. 3.11, bottom image) promote the possibility that melittin may
ultimately destroy the cell by attacking an intracellular target, at least at high
concentrations. The lack of vesiculation could alternatively be the result of stable pore
formation with melittin in a strong perpendicular orientation causing swift cell lysis without
extensive surface damage. One might suggest a possible "barrel-stave" mechanism as an
alternative, however this is unlikely, due to the electrostatic interaction between the cationic
peptide and the negatively charged head groups of the bacterial membrane surface.
Our images also support previous studies indicating that biological membranes have
specific lateral organisation and that lipid segregation occurs and has physiological
relevance [19,46]. If same-type lipids were grouped together in bands it would make certain
areas of the target membrane more vulnerable to peptide attack, depending on the
prominent curvature strain of that lipid-type. This could explain why peptide-induced
lesions on erythrocyte and bacterial membranes did not appear to be randomly distributed.
Instead, they were always connected by lines or clustered in bands across the membrane.
In summary, our results indicate that magainin 2 maintains a parallel orientation on
erythrocyte membranes, which in tum supports, a mechanism similar to the "carpeting"
model. Furthermore, melittin on erythrocytes and both melittin and magainin 2 on E. coli
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undergo membrane re-orientation. This in tum supports a ''toroidal pore" mechanism of
action.
3.6 Conclusions
AFM successfully allowed the visualization of antimicrobial peptides interacting with
target membranes without the influence of fixing agents.
In comparison with model membrane studies, the AFM results show that a peptide can
function by more than one mechanism of action depending on the structural composition of
the membrane, which appears to have a specific segregated lateral organisation. Magainin 2
(non-toxic) selectively targets cell membranes using different mechanisms of action. In this
way it can lyse bacterial membranes (anti-bacterial agent) using one mechanism, while
using another mechanism to interact with mammalian cells at physiological concentrations,
without destroying them. In contrast, melittin (toxic) is non-selective and possibly uses the
same mechanism of interaction with bacterial and mammalian membranes. Furthermore,
we propose the "Phase-transition" model as a new holistic model for the mechanism of
action of antimicrobial peptides (Chapter 4).
Future studies imaging in solution will allow visualisation under true physiological
conditions. The biological applications of AFM are still relatively new, but it is clear that
AFM will open new insights into our understanding of the mechanism of action of
antimicrobial peptides.
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Chapter 4
General Discussion
The aim of this study was to first successfully synthesise magainin 2, second develop and
optimise a new microscopy method using atomic force microscopy (AFM), and third
investigate the mechanism of action of antimicrobial peptides on target membranes using this
visualisation technique.
4.1 Peptide Synthesis
Although automation will undoubtedly pave the way for fast effective peptide synthesis, the
Fmoc-polyamide shake flask procedure used in the BIOPEP peptide laboratory is very
effective in developing not merely an understanding of peptide synthesis, but instilling a solid
foundation for chemical problem-solving in the future. One of the more important lessons
learnt was the necessity for quality control checks on all derivatives, even newly acquired
ones, prior to synthesis. This was partially the reason for the first unsuccessful synthesis,
where a suspected aspartimide reaction [1] on A22 resulted in the loss of side-chain
deprotection of S23, causing additional unwanted analogues and a decrease in peptide yield.
The aspartimide reaction can be partially suppressed by the inclusion of 1-
hydroxybenzotriazol in the cleavage/deprotection mixture [2]. In the second synthesis this
problem was prevented by rigorously testing all derivatives and activating agents, however,
attachment of the first C-terminal amino acid to the resin linker is also particularly important.
The extent of this first reaction will determine the yield of final peptide. Sites on the resin not
reacted in this initial process, can potentially become acylated in subsequent cycles, which
can lead to the formation of related C-terminally truncated by-products. That is why particular
care was taken during the coupling of the C-terminal Fmoc-Ser(tBu) and blocking of the
remaining hydroxyl-groups with tBoc-Gly. These safety measures were effective in
preventing the initial problems experienced in the first synthesis. Caution was also taken to
prevent incomplete couplings by increasing the excess of amino acid derivative during
coupling. Although mass action is a major driving force during the coupling reaction of
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peptide synthesis, the influence of extremely high reactant and product concentrations in a
solid phase system with limited soluble reactant access was underestimated. The high amino
acid derivative concentrations did not influence the success of the coupling reactions during
the first two-thirds of the synthesis, but caused coupling and deblocking problems over the
last third. This typically occurs with growing peptide chains because of steric crowding and
intersite side reactions [2]. Furthermore, this may lead to incomplete solvation of the peptide-
resin complex, sudden shrinkage of the gel matrix, and reduced reagent penetration ultimately
resulting in failure of the acylation reaction [2]. This resulted in deletion and insertion
analogues that could not be purified from the main product. So although the initial synthesis
problem was solved in the second synthesis, a new problem was inadvertently created, which
compromised the synthesis. Coupling concentrations were decreased to the recommended
three-fold excess [3] during a third synthesis, while still maintaining rigorous testing on all
the derivatives and activating agents. This prevented subsequent steric-crowding and the
formation of any truncated or insertion by-products. The fundamental lesson learnt is that
effective peptide synthesis optimisation depends on exhaustive critical analysis of failed
syntheses before undertaking new syntheses. This analysis and quality control measures
allowed the synthesis and purification of magainin 2, from a 19-resudue precursor on solid
phase, of very high purity (>96%) for use in biological and AFM experiments.
4.2 AFM Visualisation
AFM is powerful visualisation technique, however, the sensitive nature of the biological
samples made optimisation critical to success, especially as it was hypothesised that a more
authentic result may be obtained if no fixing agent was used. During the development of our
AFM technique it was observed that the greatest problems were cantilever sensitivity towards
the buffered solutions and the elasticity of the target cell surface. Typically, the buffered
solutions used to suspend our biological samples would interact with the tip. Consequently,
most of the method development was focused on optimising the suspension solutions of target
cells. This decreased interference with the cantilever tip and limited target cell damage and
stress. It is therefore essential to critically analyse the solution criteria for all biological
experiments before starting your AFM image acquisition. The softness/elasticity of the
biological samples also had to be addressed. If the cantilever force was set too high, it would
push the sample surface inwards, which would result in distorted images. This problem was
addressed with each cell type by systematically changing the force parameters until consistent
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imaging was obtained. Another important aspect is the time consuming nature of image
capturing. It takes 90-120 seconds to capture an image; so building a sufficient database can
become a time-consuming procedure due to the large variation in morphology that occurs. It
was important to capture repeatable high quality controls to ensure that the experimental
results were authentic. Our technique successfully allowed the visualization of antimicrobial
peptides interacting with target membranes without the influence of fixing agents.
The AFM results were discussed in Chapter 3, and indicate that magainin 2 maintains a
parallel orientation on erythrocyte membranes and mass accumulation on the surface results
in the formation of grooves. In relation to previous model membrane studies the mechanism
can be associated with the "carpeting" model [4]. Furthermore, melittin on erythrocytes and
both melittin and magainin 2 on E. coli undergo membrane re-orientation. Mass accumulation
results in the formation of grooves because of parallel orientation and lesions due to
perpendicular orientation. In relation to previous model membrane studies the mechanism can
be associated with the "toroidal pore" model [5,6].
In relation to results and hypothesis generated through previous model membrane studies, our
AFM results can be interpreted to show that a peptide can function by more than one
mechanism of action depending on the structural composition of the membrane, which
appears to have a specific segregated lateral organisation. Magainin 2 (non-toxic) selectively
targets cell membranes using different mechanisms of action. In contrast, melittin (toxic) is
non-selective and uses the same mechanism of interaction with bacterial and mammalian
membranes. However, these models relate to model membranes, and not necessarily
biological membranes. Model membrane studies tend to compartmentalise the mechanism of
action of a peptide to a specific lipid type providing only a snapshot of what the mechanism
would look like under those specific conditions, and not if all the components of a cell
membrane were present to influence the mechanism. We therefore believe that if all these
compartmentalised "snapshots" were combined then it cannot be excluded that the "carpet"
and the "toroidal" mechanism are subsets of one mechanism and that the structural parameters
of the peptide and the lipid membrane could determine which subset of the mechanism and
peptide orientation will be most prominent under a specific set of physiological conditions.
We know that the orientation of a peptide strongly influences the interaction with the
membrane and the mechanism of action. Yet model membrane studies still lead to
contradicting results (see 1.1.4 and Table 1.3) because of the experimental differences and
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constraints of the analysis procedures. Most analytical procedures used to determine the
orientation of a peptide, such as nuclear magnetic resonance and circular dichroism, work on
statistical averages. This means that the structure or orientation of the bulk-phase of the
molecules is determined. It is possible that the bulk-phase structure/orientation is not the
structure/orientation of the active species (see Table 1.3). Consequently, the mechanism of
action still remains in doubt.
Therefore we would like to propose a new model based on previous model membrane studies
and on our AFM results. It must be emphasised that this model is speculative, as no such
comparisons have previously been undertaken; therefore the objective is to initiate a
synergism between model membrane studies and future AFM studies on biological
membranes. With this model we hope to offer an explanation for 1) the confusion regarding
orientation using model membrane studies and 2) the variation in pore size.
4.3 The "Phase-Transition" model:
The model entails that all antimicrobial peptides function by means of one universal
mechanism, which involves a time dependent change in peptide orientation from parallel to
vertical. (Fig. 4.1).
Time-dependent increments of re-orientation from parallel to vertical
PHASE A PHASEB PHASEC PHASED
Figure 4.1 A diagram illustrating the "phase-transition" (PT) model.
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The change in orientation from parallel to vertical is not instantaneous, but takes place in
incremental time-dependent steps. lts structural parameters and those of the lipid membrane
determine the speed at which a peptide can move through each increment. If the two
complement each other the peptide will move through the orientational increments rapidly,
forming stable pores leading up to cell lysis. Intracellular targets can also possibly be reached
with the formation of stable pores. If, however, the peptide and lipid membranes are not
complementary, the peptide will move slower through each increment of orientation. An
equilibrium could possibly be found in an orientation somewhere between parallel and
vertical, which may lead to local membrane curvature changes and membrane thinning (Fig
4.2). The orientation where the peptide finds equilibrium, will determine which part of the
"phase transition" model is emphasised, and in turn the morphological damage that will lead
up to cell lysis. The nearer the peptide is to a parallel orientation, the greater the
morphological damage leading up to lysis. Therefore a peptide can still utilise the same
mechanism on different lipid compositions and cause different morphological damage,
depending on the final orientation of the peptide and therefore which part of the " phase-
transition (PT)" model is emphasised (Fig 4.2). This could explain why we saw differently
sized lesions, depending on the type of peptide and biological membrane.
If we compare our model with existing models we find that the "carpeting" model could
possibly represent PHASE A of the PT model where no pore formation is possible (Fig 4.2),
whereas the "toroidal" model could represent PHASE B-D (Fig. 4.2) where pore formation
can occur.
In conclusion, to better understand how peptide structural parameters influence the
mechanism of action, it is essential that studies move away from model membrane studies
towards studies on real target membranes. Although AFM is not the ultimate solution, it is
definitely a step in the right direction.
Future studies will focus on comparing the influence of melittin, magainin 2 and for example
alamethicin, the only known peptide with a confirmed "barrel-stave" mechanism of action, on
similar target cells that have different lipid compositions. Furthermore analysis of the
influence of melittin and magainin 2 on model membranes using AFM could clarify some of
the contradictory results found so far.
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Figure 4.2 The PT model using hypothetical AFM images as a demonstration of possible
morphological damage as a result of peptide phase transitions.
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